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 The mutant prevention concentration (MPC) is defined as the lowest antimicrobial 
concentration required to inhibit the growth of the least susceptible bacterial cell based on 
an inoculum of ≥109 colony forming units (CFUs).  The current protocol for MPC testing 
is technically demanding and time-consuming which limits its implementation into 
clinical microbiology laboratories.  In an attempt to simplify the current MPC protocol 
we developed a modified MPC method, the microbroth dilution method, which requires 
two fewer days to complete than the current or traditional method.  MPC values were 
consistent for all organisms and strains tested using both the traditional MPC method and 
the modified microbroth dilution MPC method.    
 Tigecycline is the first of a new class of compound – glycylcyclines- with potent 
in vitro activity against Gram-positive organisms including penicillin-resistant and multi-
drug resistant Streptococcus pneumoniae (SP) and methicillin-resistant Staphylococcus 
aureus (MRSA).  We measured minimum inhibitory concentration (MIC) and MPC 
values for tigecycline against 47 clinical isolates of SP and found that the MPC90 values 
were >500 fold higher than the MIC90 values.  To determine if MPC testing of 
tigecycline against SP is impacted by blood in the medium, we developed a new medi
able to sustain the growth of SP without the need for blood; solidified Todd-Hewitt
(sTHB).  The MPC90 values of tigecycline against SP on sTHB were only 2 fold higher 
than the MIC90 values.  When blood was added to the sTHB, the MPC90 values again 
became much greater than the MIC90 values (> 256 fold higher).  MPC results for 
Staphylococcus spp. against tigecycline were not impacted by blood in the medium.  
  iii
 Benzalkonium chloride (BAK) is a cationic surface-acting agent that acts on 
bacterial cells by disrupting the intermolecular interaction of the lipid bilayer.  To 
determine if the fluoroquinolones gatifloxacin (Gfx) and moxifloxacin (Mfx) are more 
active (lower MIC values) in the presence of BAK, we conducted MIC, MPC, and time-
kill assays.  MIC testing showed that in the presence of 3.125 to 50 µg/ml of BAK, the 
MIC of Gfx and Mfx decreased by 8- to 5000-fold against clinical isolates of methicillin-
susceptible Staphylococcus aureus (MSSA), MRSA, Coagulase-negative Staphylococci 
(CNS), SP, Escherichia coli (EC), and Pseudomonas aeruginosa (PA).  MPC testing 
showed that the presence of 7 to 10 µg/ml of BAK, the MPC of Gfx and Mfx decreased 
by 32- to 1000-fold against clinical isolates of MRSA.  Conventional time-kill studies 
(using a bacterial load of 105 CFUs) showed that the killing activity of Gfx against 
clinical MRSA isolates was enhanced in the presence of BAK with a log10-reduction 
(percent kill) of 1.6 (76.08%) for Gfx alone at 180 minutes compared to a log10-
redecution (percent kill) of 5.4 (100%) for Gfx plus BAK at 180 minutes. 
 Alexidine (Alx) is a bisbiguanide that has been used as an effective disinfectant in 
the dental industry and is potentially being developed for use as an antimicrobial agent 
for ocular infections.  We conducted susceptibility testing of Alx using MIC testing, 
MPC testing, and time-kill assays against Gram-positive and Gram-negative pathogens.  
MIC testing showed that Alx is more active against Gram-positive pathogens than Gram-
negative pathogens and showed better activity than the fluoroquinolones Gfx, Mfx, and 
levofloxacin (Lfx) against MRSA.  The MPC values measured for MRSA and MSSA 
against Alx were non-reproducible using the traditional MPC method.  Using the 
microbroth dilution MPC method, MPC90 values were found to be 32 fold higher than the 
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MIC90 values.  If the experimentally determined MPC values are “true” MPC values, 
initial MPC testing indicates that Alx may have a high likelihood for selecting for 
resistance, however, if the MPC values are not accurate it may be necessary to modify the 
MPC protocol in order to complete MPC testing of Alx against MRSA and MSSA.  
Conventional time-kill studies (using a bacterial load of 105 CFUs) measured bactericidal 
activity (> 3 log10-reduction) against MRSA, MSSA, SP, and PA. 
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1.0 INTRODUCTION 
1.1 Antimicrobial Resistance 
With the initial discovery and introduction of Penicillin G in the early 1940s the 
pre-antibiotic age ended; an age when simple bacterial infections often meant life-
threatening disease and death [1]. Unfortunately, by 1944 antimicrobial resistance had 
already appeared with strains of penicillin-resistant Staphylococcus aureus being reported 
[2].  With great foresight, Alexander Fleming, who won the Nobel Prize in 1945 for the 
discovery of penicillin, warned in 1946, “…the greatest possibility of evil in medication 
is the use of too small doses so that instead of clearing up infection the microbes are 
educated to resist penicillin and a host of penicillin-fast organisms is bred out, which can 
be passed to other individuals and from them to others, until they reach someone who 
gets septicemia or pneumonia which penicillin cannot save” [3].  Unfortunately, we did 
not heed Fleming’s warning and nearly sixty-five years later, virtually all strains of 
Staphylococcus aureus are resistant to natural penicillins [2].  According to the National 
Nosocomial Infections Surveillance (NNIS) system report for 2004, 59.5% of 
Staphylococcus aureus strains in intensive care unit (ICU) patients were methicillin-
resistant [2, 4].  According to the Canadian bacterial surveillance network (CBSN) the 
prevalence of penicillin-resistant Streptococcus pneumoniae was virtually non-existent in 
the early 1980s, but by 2005, 15% of Streptococcus pneumoniae isolates were penicillin-
resistant [5]. Unfortunately the development of antimicrobial resistance is not limited to 
penicillins; in fact, bacterial evolution has culminated in the emergence of resistance to 
every approved antibiotic [1, 2, 6, 7].  Antimicrobial resistance was recently described by 
Blondeau et al as a global pandemic [8-10].  This definition seems fitting as antimicrobial 
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resistance is a growing concern worldwide with more and more bacterial organisms 
developing resistance to an ever-increasing number of antimicrobial agents [11, 12].  
Resistance rates are increasing among Gram-positive and Gram-negative organisms and 
the increase in multi-drug resistant (MDR) organisms is very troubling as they are 
increasingly difficult to treat [1, 2, 6, 7, 11, 13].  Reported rates of MDR isolates from 
intensive care units in the U.S. increased from 4% in 1993 to 14% in 2002 and rates of 
MDR Pseudomonas aeruginosa increased from 12.8% in 1997 to 20.8% in 2000 [11].  
1.2 Factors Leading to Antimicrobial Resistance 
 Virtually all genera and species of pathogenic bacteria are either innately resistant 
or acquire resistance to antimicrobial agents [9].  For organisms to be innately resistant to 
a particular antimicrobial agent (or class of antimicrobial agents) they must possess an 
inherited trait that allows them to resist the killing or inhibitory effect of the antimicrobial 
agent(s).  Of greater concern are organisms which have acquired resistance; where a 
bacterial population initially susceptible to an antimicrobial agent or class has become 
resistant to that agent allowing the population to proliferate and spread under the 
selective pressure of that agent [9, 14].  One of many ways bacteria acquire resistance is 
through the acquisition of genes encoding enzymes that destroy the antimicrobial agent 
before it can have an effect.  These genes can be acquired by any one of several genetic 
mechanisms, including transduction, transformation, and conjugation and because of 
these genetic mechanisms it is not uncommon for some organisms to have several 
resistance mechanisms, potentially conferring on them resistance to multiple classes of 
antimicrobial agents [9, 14].  Bacteria that are resistant to three or more antimicrobial 
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classes are defined as multi-drug resistant (MDR) organisms and are of serious concern 
because of their potential difficulty to be treated [14].   
Spontaneous mutation and the acquisition of genes encoding efflux pumps are 
two additional ways in which bacteria are able to resist the effects of antimicrobial agents.  
Efflux pumps function by expelling the antimicrobial agent from the bacterial cell before 
it can exert its biological effect while spontaneous mutations are able to confer resistance 
many different ways including, the alteration of target proteins to which antimicrobial 
agents bind [14].  While it is highly unlikely that a single genetic mutation would result 
in high-level resistance to an antimicrobial agent, it may allow the bacterial cell 
containing the mutation to survive long enough to acquire additional mutations or 
resistance mechanisms [15].  There are reports, although rare, of high-level antimicrobial 
resistance caused by a single mutation [14].    
There are several factors that have been attributed to causing or have been 
associated with antimicrobial resistance.  These include but are not limited to the 
following: over-prescription of antimicrobials, the use of inappropriate antimicrobials, 
incorrect dosage of antimicrobials, veterinary use of antimicrobials, clinical trials 
excluding patients with resistant pathogens, and clinical trials which focus solely on 
clinical outcomes [8].  While there is little doubt that all of these factors contribute to 
antimicrobial resistance, it is widely accepted that the main causes have been, and still are 
widespread inappropriate use and over-prescribing of antimicrobial agents in clinical 
practice [7, 16].  In a study conducted by Rybak and associates, indiscriminate antibiotic 
treatment was found by looking at 100 consecutive patients prescribed fluoroquinolones 
in the emergency departments of two institutions and subsequently discharged.  After 
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reviewing the appropriateness of these prescriptions, Rybak and associates determined 
that 81 of the 100 patients received a fluoroquinolone inappropriately.  Of the 19 patients 
treated appropriately with a fluoroquinolone (as determined by guidelines and cause of 
infection), only one was prescribed the correct dosage and treatment duration [17].  In 
fact, data in the US indicate that at least half of patients diagnosed with infections caused 
largely by respiratory viruses received antibiotic therapy [18].   
1.3 Ocular Infections  
Common ocular infections such as conjunctivitis, keratitis, and endophthalmitis 
are caused by a diverse group of bacterial, viral, and fungal pathogens and treatment 
therefore includes the use of antivirals, antifungals, and antibacterial agents [19].  
Bacterial keratitis is the leading cause of blindness in the developing world while 
conjunctivitis is one of the leading causes of visits to the emergency room or doctor’s 
office in the developed world [20-23].  As contact-lenses become more popular, the 
incidence of bacterial keratitis has significantly increased with current estimates 
reflecting 10-30 cases per 100,000 people using contact lenses annually [21].  Gram-
positive cocci, especially Staphylococcus spp., are by far the most common cause of 
bacterial ocular infections [24, 25].  Other important bacterial organisms involved in 
ocular infections include Streptococcus pneumoniae, Haemophilus spp., Moraxella spp., 
Corynebacterium diphtheriae, and Neisseria spp. [21].   
Three fluoroquinolones were introduced in the 1990s for topical use of common 
bacterial infections such as conjunctivitis and keratitis; these fluoroquinolones were 
ciprofloxacin 0.3%, ofloxacin 0.3%, and norfloxacin 0.3% [26].  Fluoroquinolones were 
welcomed in the field of ophthalmology because of their good penetration and relatively 
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broad-spectrum activity; they were also shown to be equivalent to combination therapy in 
the treatment of many ocular infections [19, 27, 28].  Unfortunately, since their 
introduction, in vitro resistance to these three fluoroquinolones has been steadily rising 
among both Gram-positive and Gram-negative organisms [22, 26, 29-31].  In a 16 year 
study conducted by Davis et al and later summarized by Blondeau, significant resistance 
was found to ciprofloxacin and ofloxacin; 606 bacterial endophthalmitis isolates were 
analyzed and in 1994, 1997, and 2000 the percentage of Staphylococcus aureus isolates 
resistant to ciprofloxacin was 32%, 42%, and 67% respectively [24, 31].  Similar trends 
were seen in resistance to ofloxacin [24, 31].  
Three new fluoroquinolones were recently introduced and approved for topical for 
ocular indications; levofloxacin 0.5% in August 2000, gatifloxacin 0.3% in March 2003, 
and moxifloxacin 0.3% in April 2003.  These new fluoroquinolones have enhanced 
Gram-positive activity (lower MIC values) when compared to the older fluoroquinolones 
ciprofloxacin and ofloxacin [26, 32].  Gatifloxacin and moxifloxacin use a unique dual-
binding mechanism of action in Gram-positive organisms and, therefore, represent the 
most advanced group of compounds within the fluoroquinolone class [19].  Not only are 
these two antimicrobial agents more active against Gram-positive organisms than 
previous agents, but they also provide less opportunity for the emergence of 
fluoroquinolone-resistant populations [28].  The addition of a unique bicyclic side chain 
at C-7 on the molecular structure decreases the risk for resistance by inhibiting the 
bacterial efflux pump mechanism [19, 26, 33].  Unfortunately, despite their advanced 
structure and better spectrum of activity, there have been recent reports of emerging 
resistance against gatifloxacin and moxifloxacin [28, 34].  
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1.4 Fluoroquinolones 
 The first quinolone antibiotic, nalidixic acid, was introduced in 1962 and was an 
antibiotic by-product in the synthesis of chloroquine [35].  Nalidixic acid had good in 
vitro antibacterial activity against Gram-negative cocci and therefore was of clinical use 
in uncomplicated urinary tract infections [36].  In an effort to improve the spectrum of 
activity of nalidixic acid, several structural modifications were made which ultimately 
resulted in four generations of quinolones, each with a broader spectrum of in vitro 
antibacterial activity (Figure 1.1) [28, 35].  The second generation quinolones were 
introduced in the 1980s, and included ciprofloxacin, norfloxacin, and ofloxacin. The 
second generation fluoroquinolones were developed by adding a fluoro-group at position 
6 resulting in limited antimicrobial activity against Gram-positive organisms while 
retaining good antimicrobial activity against Gram-negative organisms [35].  These 
compounds are referred to as fluoroquinolones.  
The classification of third and fourth generation fluoroquinolones is somewhat 
unclear.  From a systemic treatment perspective, antimicrobial agents such as 
levofloxacin, gatifloxacin, and moxifloxacin are third generation fluoroquinolones [37].  
However, in the field of ophthalmology, levofloxacin is considered a third generation 
fluoroquinolone while gatifloxacin and moxifloxacin are both considered fourth 
generation fluoroquinolones [19, 28].  The newer fluoroquinolones contain modifications 
at the C-5, C-7, and C-8 positions which further enhance their Gram-positive activity.  
The introduction of the NH2 group at C-5, the alkylation of the piperazine group at C-7, 
and the addition of a methoxy group at C-8 all resulted in an increase in anti-Gram-
positive activity [35].  The newer fluoroquinolones therefore exhibit good in vitro  
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antimicrobial activity against Gram-positive and Gram-negative organisms [19, 27]. 
1.4.1 Mechanism of Action 
 The fluoroquinolones act on bacterial cells by inhibiting two enzymes involved in 
bacterial DNA synthesis; DNA gyrase and topoisomerase IV.  Human cells lack both of 
these enzymes therefore enabling these agents to be specific [19, 27].  DNA gyrase is 
responsible for introducing negative supercoils into the DNA double helix ahead of the 
replication fork resulting in the separation of replicated daughter chromosomes [19, 23, 
38, 39].  DNA gyrase is composed of two monomeric subunits, GyrA and GyrB, encoded 
by the gyrA and gyrB genes respectively.  Topoisomerase IV segregates daughter 
chromosomes at the end of a round of replication in a process known at decatenation.  
Decatenation involves removing the interlinking of daughter chromosomes after 
replication; it also results in relaxation of the supercoiled DNA [19, 27].  Topoisomerase 
IV is composed of four homologous monomeric subunits, two ParC subunits and two 
ParE subunits, encoded by the parC and parE genes respectively.  The structure and 
function of DNA gyrase and topoisomerase IV are detailed in Figure 1.2.  When 
fluoroquinolones interact with the DNA-enzyme complex, they create a conformational 
change that results in the inhibition of normal enzyme activity.  DNA synthesis is 
ultimately inhibited and the bacterial cell experiences rapid bacterial cell death [19]. 
For the older fluroquinolones, DNA gyrase is the target enzyme for most Gram-
negative organisms while topoisomerase IV is the target enzyme for most Gram-positive 
organisms [27].  An important feature of the newer fluoroquinolones, such as gatifloxacin 
and moxifloxacin, is their dual activity (i.e. they are able to act on both DNA gyrase and 
topoisomerase IV) [41].  This is an important feature; dual activity fluoroquinolones
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Figure 1.2: Structure and principal function of DNA gyrase and topisomerase IV [40]. 
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require a bacterial isolate to contain a double mutation (mutations in each of the parC and 
gyrA genes) in order to resist their antimicrobial effect. 
 1.4.2 Mechanisms of Resistance 
The fluoroquinolones are subject to various mechanisms of resistance, including, 
point mutations in gyrA or gyrB, point mutations in parC or parE, membrane-associated 
efflux proteins (norA), and a locus (flqA) which confers quinolone resistance in 
Staphylococcus aureus [27].  Point mutations in DNA gyrase are most commonly found 
in Gram-negative organisms, whereas point mutations in topoisomerase IV are most 
commonly found in Gram-positive organisms [40].  These point mutations are most 
commonly seen in areas of the bacterial genome known as quinolone resistance 
determining regions (QRDRs).  The single target action of older fluoroquinolones makes 
them especially vulnerable to single mutations and as such single mutations are able to 
significantly affect the potency of these older drugs.  Due to the dual activity of the newer 
fluoroquinolones, single mutations have little effect on the potency of these newer 
fluoroquinolones (i.e. gatifloxacin and moxifloxacin) [41].   
 Efflux-mediated resistance is a growing problem in the quest to develop potent 
antimicrobial agents and efflux mechanisms have been shown to make a particularly 
important contribution to fluoroquinolone resistance [27].  The main gene involved in 
bacterial-mediated efflux of fluoroquinolone antibiotics is the norA gene [27].  
Dependent on the proton motive force, the norA gene mediates the efflux of drug from 
the bacterial cell, although its exact mechanism of action is unclear [42]. 
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1.5 Novel Antimicrobial Agents 
  There have been only a few new antimicrobial agents approved for use in the last 
ten years and even more concerning is the fact that very few new antimicrobial agents are 
in the pipeline to be marketed in the future [11].  Since 1998 only ten new antibacterial 
agents have been approved by the U.S. Food and Drug Administration (FDA) and only 
three of these had novel mechanisms of action; linezolid, daptomycin, and tigecycline 
(approved in 2000, 2003, and 2005 respectively).  Out of the three antibacterial agents 
with novel mechanisms of action only tigecycline has a broad spectrum of activity [43].  
Shockingly, approval of new antibacterial agents by the FDA decreased by 56% from 
1983-1987 to 1998-2002 [17].  We are in dire need for new antimicrobial agents, 
particularly with different mechanisms of action [14, 43]. 
 1.5.1 Cationic Antimicrobial Agents 
Cationic antimicrobial agents have been used for over a century in both infection 
control and within many consumer products including: pool/hot tub disinfection products, 
biocidal bandages, hair care products, baby diapers, inks, and mouthwash/dental 
preparations [44].  Two classes of cationic antimicrobial agents that have been in use for 
over 40 years include the quaternary ammonium compounds (QACs) and the 
bisbiguanides [16].  Bisbiguanides are well known anti-plaque agents and play a critical 
role in the reduction of supragingival plaque and treatment of gingivitis, while QACs are 
used extensively in the food processing industry to prevent the persistence of pathogens 
such as Escherichia coli and Listeria monocytogenes [16, 45-47].  Two antimicrobial 
agents discussed in the next section, benzalkonium chloride (BAK) and alexidine are 
QACs and bisbiguanides. 
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 Cationic antimicrobial agents are bactericidal agents that exert their effect by 
binding to the bacterial cell surface and integrating themselves into the cytoplasmic 
membrane.  This cellular disruption is generally sufficient to cause the membrane to lose 
fluidity and for the bacterial cell to die [16].  All that these cationic agents require to 
interact with a bacterial cell surface is a strong positive charge together with a 
hydrophobic region.  The strong positively charged cationic molecules are able to bind to 
bacterial cells because of the opposite negative charge of bacterial cell walls.  
Bisbiguanides carry two cationic groups while QACs are generally monocationic [16]. 
  1.5.1.1 Benzalkonium chloride     
 Benzalkonium chloride (BAK) is a cationic antimicrobial agent belonging to the 
quaternary ammonium compound (QAC) family.  It is currently being used as a 
preservative in the commercial preparation of Zymar® (0.3% gatifloxacin plus 0.005% 
BAK).  Zymar®, a registered tradename of Allergan, Inc., is a topical ophthalmic solution 
indicated for treatment of bacterial conjunctivitis caused by susceptible strains of 
Corynebacterium propinquum, Staphylococcus aureus, Staphylococcus epidermidis, 
Streptococcus mitis, Streptococcus pneumoniae, and Haemophilus influenzae.  Recent 
studies indicate that BAK used in commercial preparations, such as Zymar®, may not 
only act as a preservative, but may also contribute to a clinical effect [48].  Our lab has 
shown that the addition of BAK to gatifloxacin or moxifloxacin results in a reduction of 
the MICs provided by gatifloxacin or moxifloxacin without BAK [24, 49, 50].  
In describing the action of QACs such as BAK, Salton and associates proposed 
the following sequence of events: (i) adsorption and penetration of the agent into the 
bacterial cell wall; (ii) reaction with the cytoplasmic membrane followed by membrane 
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disorganization; (iii) leakage of intracellular low-molecular weight material; (iv) 
degradation of proteins and nucleic acids; and (v) wall lysis caused by autolytic enzymes 
[51].  A cartoon detailing the mechanism of action at the molecular level is shown in 
Figure 1.3. First, the positively charged quaternary nitrogen associates with the head 
groups of phospholipid bilayer within the membrane (Figure 1.3b).  The hydrophobic tail 
then interdigitates into the hydrophobic membrane core (Figure 1.3b, c).  As the 
concentration of QACs increases, the membrane core decreases in hydrophobicity and the 
phospholipids rearrange towards a stable hexagonal arrangement (Figure 1.3e, f).  The 
formation of the QAC/phospholipid micelles causes bacterial cell lysis [16].  This 
appears to be a bactericidal effect.    
  1.5.1.2 Alexidine 
Alexidine (2-ethyl hexyl bisbiguanidine dihydrochloride) is a cationic 
antimicrobial agent belonging to the bisbiguanide family.  As shown in Figure 1.4 by the 
two shaded outer circles, alexidine is a dimer with two active sites (i.e. two cationic 
groups) [52].  It has been used in the dental industry as a safe and effective disinfectant 
for decades and is currently being looked at as a possible antimicrobial agent for use in 
the field of ophthalmology [44].  I performed an Ovid medline search but was unable to 
find anything published on the ocular effect of alexidine. 
 Alexidine’s mechanism of action against bacterial cells is very similar to that of 
BAK.  Briefly, the positively charged cationic groups associate strongly with exposed 
anionic sites on the cell membrane and cell wall; they bind in particular to the head 
groups of the bacterial phospholipids.  Binding of alexidine to the bacterial cell is 
stronger than the binding of BAK [16, 53].  Disruption and eventual lysis of the target 
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Figure 1.3: Cartoon showing the mechanism of action for quaternary ammonium 
biocides. The segments (a–f) show progressive adsorption of the quaternary headgroup to 
acidic phospholipids in the membrane with increasing QAC exposure/concentration. This 
leads to decreased fluidity of the bilayers and the creation of hydrophilic voids in the 
membrane. Protein function is perturbed with an eventual lysis of the cell, and 
solubilization of phospholipids and proteins into QAC/phospholipid micelles. Inset 
micrograph shows vesicle formation from outer membrane caused by QAC treatment 
[16]. 





Figure 1.4: Chemical structure of the bisbiguanide alexidine. Cationic phospholipid 
binding sites are indicated by the two outer circles. Hydrophobic hexamethylene group 
indicated by the centre circle [16]. 
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bacterial cell is brought about by the binding and disruption at these sites.  A cartoon 
detailing the mechanism of action at the molecular level is outlined in Figure 1.5.  It is 
evident from the cartoon that one of the major differences between alexidine and BAK is 
that hydrophobic regions of BAK become solubilized within the hydrophobic core of the 
cell membrane while those of alexidine do not [16].  The hydrophobic region of alexidine, 
represented by the inner shaded circle in Figure 1.4, is somewhat inflexible and is 
therefore incapable of folding sufficiently to interdigitate into the lipid bilayer [16].  
Alexidine therefore bridges between pairs of adjacent phospholipid headgroups (Figure 
1.5d).  The end result is cellular leakage and bacterial cell death.  This appears to be a 
bactericidal effect.  
 1.5.2 Tigecycline   
Tigecycline is the first agent in a new class of antimicrobial agents, the 
glycylcyclines, which are semi-synthetic tetracyclines.   As such tigecycline is 
structurally similar to the tetracycline family.  Structural modifications of the four-ring 
carbocyclic structure characteristic of the tetracyclines resulted in tigecycline; 
specifically the t-butyglycylamido group was added at C-9 (Figure 1.6).  The basic 
nitrogen of the glycyl unit is vital to the preservation of antibacterial activity [54].  
Tigecycline is the only new antibiotic to be developed within the past 10 years to have a 
novel mechanism of action and broad-spectrum activity against bacterial organisms [43].  
Tigecycline demonstrates broad-spectrum in vitro and in vivo activity against a wide 
spectrum of aerobic and anaerobic Gram-positive and Gram-negative organisms 
including resistant strains such as methicillin-resistant Staphylococcus aureus, penicillin-
resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus, and extended- 
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Figure 1.5: Diagramatic representation of the interaction of alexidine with the bacterial 
cytomplasmic membrane. Diagram shows progressive decreases in fluidity of the outer 
leaflet with increasing exposure to the bisbiguanide [16]. 
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Figure 1.6: The molecular structure of tigecycline.  
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spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae [12, 54-
57].  The United States Food and Drug Administration (FDA) approved tigecycline in 
June of 2005 for the treatment of complicated skin and skin structure infections and 
complicated intra-abdominal infections.  Tigecycline is also approved for use in Canada. 
  1.5.2.1 Mechanism of Action 
Tigecycline is a bacteriostatic antimicrobial agent that inhibits bacterial protein 
synthesis by binding to the 30S ribosomal subunit.  The tetracyclines and glycylcyclines 
(i.e. tigecycline) share a binding site on the 30S ribosomal subunit, but the glycylcyclines 
interact directly with an additional site that the tetracyclines do not [58].  This additional 
binding allows tigecycline to bind five-fold more strongly to the ribosome than the 
tetracylines [43, 56].  Binding to the bacterial ribosome prevents translation by blocking 
the entry of amino-acyl transfer RNA into the ribosome and ultimately by preventing the 
incorporation of amino acids into the elongating peptide chain.  The binding of 
tigecycline to the 30S ribosomal subunit is reversible, accounting for the bacteriostatic 
activity of tigecycline against susceptible organisms.  
 Tigecycline was developed in response to the growing resistance of Gram-
positive and Gram-negative organisms to tetracycline [43].  The two major mechanisms 
of tetracycline resistance are ribosomal protection and active efflux of drug from the 
inside of the bacterial cell [12, 43, 56].  In studies thus far, it appears that tigecycline is 
able to evade these resistance mechanisms commonly affecting tetracyclines.  It is 
believed that tigecycline’s ability to overcome these two resistance mechanisms is due to 
steric hindrance created by the large substituent (t-butylglycylamido) at C-9 [54]. 
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1.6 Determining Antimicrobial Susceptibility 
One of the most important ways to prevent or reduce antimicrobial resistance is to 
treat infections with the appropriate antimicrobial agent at the appropriate concentration 
[11, 59, 60].  If used at an “appropriate” concentration, an antimicrobial agent should be 
able to prevent the growth of all susceptible and resistant bacterial cells within a cell 
population [8].  In a clinical setting, the clinical microbiology laboratory tests to 
determine the susceptibility of bacterial isolates from patient specimens to different 
antimicrobial agents.  There are a number of types of susceptibility tests available, and 
the sensitivity and specificity of these tests can vary [61, 62].  In North America, an 
organism is called susceptible if its experimentally determined minimum inhibitory 
concentration (MIC) value for a particular antimicrobial agent meets or falls beneath the 
susceptibility breakpoints set forth by the Clinical Laboratory and Standards Institute 
(CLSI).  In Europe susceptibility breakpoints are set by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST). To date, considerations in the setting of 
these breakpoints include the distribution pattern of MICs as well as the association 
between MIC and clinical efficacy [61, 63]. 
 1.6.1 Minimum Inhibitory Concentration 
The minimum inhibitory concentration (MIC) is defined as the lowest 
concentration of antimicrobial agent required to inhibit bacterial growth of an inoculum 
containing 105 colony forming units (CFUs) per milliliter (ml)  [64].  Using CLSI 
susceptibility breakpoints, a bacterial strain can be characterized as susceptible, of 
intermediate resistance, or resistant to a particular antimicrobial agent on the basis of 
MIC values.  There are currently several methods used to determine MIC values for 
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specific antimicrobial agent-bacterial organism combinations.  These methods include but 
are not limited to the microbroth dilution method, the disc-diffusion method, the E-test 
method, and automated methods such as the VITEK system (BioMerieux, St. Laurent, 
QC).   Standard protocols for all aforementioned tests are found in the CLSI and 
EUCAST guidelines [65, 66]. 
Minimum inhibitory concentration testing is a globally standardized and accepted 
test of susceptibility, however, there are several limitations involved with the use of MIC 
testing.  One of the major limitations of using MIC values as a guideline for determining 
antibiotic susceptibility is that MIC values are experimentally determined using an 
organism density of 105 CFU/ml.  In 1942, Firsch and colleagues estimated that a 
bacterial burden of 1010 to 1012 CFUs was present during an acute infection in patients 
with pneumococcal pneumonia [67].  It seems reasonable that many more patients may 
be infected with greater numbers of bacterial organisms than those that are used in our 
current standardized MIC susceptibility testing (i.e. 105 CFU/ml).  Another important 
limitation of MIC testing is that it in no way indicates the possibility or extent of 
resistance selection.  The mutant prevention concentration (MPC) was developed as a 
method to overcome the limitations of MIC testing.   
 1.6.2 Mutant Prevention Concentration 
 The mutant prevention concentration (MPC) is defined as the lowest 
concentration of antimicrobial agent required to inhibit the least susceptible bacterial cell 
in a bacterial inoculum of ≥109 CFUs [8, 10, 68].  The term “mutant prevention 
concentration” was coined by Dong et al in 1999, following the recognition of a two-
stage decline in CFUs when high-density bacterial inocula were exposed to varying 
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antimicrobial drug concentrations (Figure 1.7) [69].  Dong et al found that with 
increasing fluoroquinolone concentration there were two sharp decreases in the fractions 
of viable cells recovered when wild-type cells were used in experiments (in this case 
Mycobacterium bovis BCG and Staphylococcus aureus).  The first decrease occurred at a 
fluoroquinolone concentration approximating the MIC99 of the wild-type cells used.  The 
second decline in recovered viable cells occurred at a higher fluoroquinolone 
concentration and followed a plateau region (i.e. a concentration range in which the 
recovery of viable cells decreased very gradually).  Nucleotide sequence analysis of 
colonies recovered from the plateau region revealed mutations in the QRDR of GyrA 
(Mycobacterium bovis BCG) and ParC (Staphylococcus aureus).  The authors concluded 
that the second large decline in viable cells occurred once the fluoroquinolone 
concentration was sufficient to block the growth of these first-step mutants; a 
concentration they termed the mutant prevention concentration [69]. 
 The concept of the MPC is increasingly important because there are data to 
suggest that many patients may be infected with greater numbers of bacterial organisms 
than those that are used in our current standardized MIC susceptibility testing (i.e. 105 
CFUs), as described earlier [10, 67]. The MPC is experimentally determined using a 
bacterial burden that may more closely reflect the situation found in clinical infection (i.e 
≥109 CFUs).  For fluoroquinolones, mutations are thought to occur at a rate of 1x10-7 to 
1x10-9 [68].  Therefore, in order for a bacterial strain to grow in the presence of an 
antimicrobial agent present at the MPC concentration, it would require more than one 
mutation.  The rationale for this is as follows: at a mutational frequency of 10-7, more 




Figure 1.7: Effect of fluoroquinolone concentration on selection of resistant mutants. M. bovis BCG isolate KD1295 (A) and 
S. aureus MT5 (B) were plated on agar containing the indicated concentrations of PD161148, a C-8-methoxy compound (open 
squares), PD160793, a C-8-H derivative (filled squares), or ciprofloxacin (open circles). Panel A also shows the responses of the 
M. bovis BCG first-step mutant CX1 (3) to ciprofloxacin (filled circles); in panel B, half-filled squares show the responses of a first-
step parC (Cipr) mutant of S. aureus (strain KD1806) to treatment with the indicated concentrations of PD160793. After incubation to 
allow growth, colonies were counted, and the fraction of the input number was determined. In the experiments shown, up to 1011 cells 
were applied to agar plates. The MIC99 for each compound is indicated by arrows. Small arrowheads on the abscissa indicate the 
MPC1010 for the C-8-methoxy compound (m), C-8-H compound (h), and ciprofloxacin (c) [69]. 
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mutations.  A bacterial load of 1014 is higher than that present during infectious diseases 
[8, 59]. 
 Some authors have suggested that the MPC method of testing only applies to 
fluoroquinolone compounds [70].  Subsequently, numerous studies have experimentally 
measured MPC values against a wide variety of antimicrobial agents and bacterial 
pathogens [10]. It is important to remember that MPC defines the mutant prevention 
concentration and not the mutation prevention concentration.  The MPC is used to 
determine the antimicrobial concentration required to block the growth of the least 
susceptible cell in the population and is independent of the mechanism of resistance. 
1.6.2.1 The Mutant Selection Window 
The mutant-selection window (MSW) defines an antimicrobial concentration 
range in which the antimicrobial-resistant mutant subpopulation (present prior to 
treatment) is selectively amplified (Figure 1.8).  The lower boundary of the MSW is the 
MIC, at which growth of all antibiotic-susceptible bacterial cells is inhibited.  The upper 
boundary is defined by the MPC which blocks the growth of the least susceptible 
bacterial cell in the population.  The MSW postulates that antimicrobial concentrations 
falling within the “window” may selectively amplify the resistant subpopulation present 
as part of the total bacterial burden [8, 10, 59].  We have previously demonstrated in vitro 
that when drug concentrations are in excess of the MPC, both susceptible and mutant 
organisms are inhibited [8].  When drug concentrations fall below the MIC, neither 
mutant nor susceptible cells are inhibited.  For drug concentrations that fall within the 
MSW, susceptible cells are likely to be inhibited as the drug concentration is in excess of 
the MIC; however, mutant cells will not be inhibited as the drug concentration is below 






















Figure 1.8: Mutant-selection window.  
MIC: Minimum inhibitory concentration; MPC: Mutant-prevention concentration; MSW: 
Mutant-selection window [10]. 
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the MPC.  Therefore, although therapeutic drug concentrations used in clinical practice 
today lead to clinical cure, they may in fact be the same drug concentrations that are 
selectively amplifying the mutant subpopulation present in high-density bacterial burdens 
(Figure 1.9) [10].  Blondeau points out that “while not all resistance results in clinical 
failure, antimicrobial resistant pathogens increase the risk of drug failure” [71]. 
1.7 In vitro Growth Dynamics 
1.7.1 Time-Kill Curves 
 Bacterial susceptibility testing methods such as MIC and MPC are useful tools for 
determining drug-concentrations required to inhibit bacterial growth in vitro, however, 
these tests reveal nothing about the killing potential of an antimicrobial agent [71].  
Time-kill experiments are performed to measure the log10-reduction and percent kill of 
viable bacterial cells when exposed to different antimicrobial agents.  One limitation of 
time-kill experiments is that these studies have a constant amount of drug (i.e. there is no 
drug elimination over time as there is in humans) [8].  In spite of this limitation, these 
experiments remain valuable tools, as the bacterial load, antimicrobial concentration, and 
duration of the assay can all be controlled as desired.   
1.8 Summary  
 Antimicrobial resistance is a growing concern worldwide.  If bacterial pathogens 
continue to develop resistance to antimicrobial agents at the current rate, we will 
inevitably end up in a situation that resembles the pre-antibiotic era in which no 
therapeutically-useful antibiotics are available.  In order to prevent an era where people 
will once again die from simple bacterial infections, it is critical that as a society we take 
measures to ensure the responsible use of antimicrobial agents.  One of the most 
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Figure 1.9: Cartoon illustrating potential treatment outcomes using both MIC and MPC 
drug concentrations. 
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important means of reducing the selective pressure that helps resistant organisms emerge 
is using the appropriate drug at the appropriate dosage and for the appropriate duration 
[14].     
The current susceptibility breakpoints, as outlined in the CLSI or EUCAST 
guidelines, may actually be providing physicians with dosing information that is 
ultimately leading to increased antibacterial resistance.  In susceptibility testing, there is a 
need for methods that can give an indication of the possibility or extent of resistance 
selection; the MPC method is one such method.  Use of the MPC method in clinical 
laboratories may be one potential answer to the global pandemic of antimicrobial 
resistance. 
1.9 Objectives 
 Four main objectives were established for this graduate research project.  The first 
objective was to develop new experimental methods for determining MPC values.  The 
second objective was to determine if MPC testing of tigecycline against S. pneumoniae is 
impacted by media, specifically media containing blood.  The third objective was to 
determine whether the flouroquinolones gatifloxacin and moxifloxacin, are more active 
(lower MIC values) against bacterial pathogens in the presence of BAK.  The fourth and 
final objective was to conduct susceptibility testing of Alexidine using MIC testing, MPC 
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2.0 MATERIALS AND METHODS 
2.1 Standard Laboratory Methods 
2.1.1 Isolate Collection and Identification 
 Clinical isolates of Staphylococcus aureus (MRSA, MSSA, CNS), Streptococcus 
pneumoniae, Escherichia coli, Haemophilus influenzae, and Pseudomonas aeruginosa 
were collected (2000-2007) from the Clinical Microbiology Laboratory, Royal University 
Hospital, Saskatoon, SK.  Isolates were from patients with various infections and were 
identified by Vitek (BioMerieux, St. Laurent, QC) and other reference procedures as 
summarized in the Manual of Clinical Microbiology [64].  Methicillin-resistance was 
detected by inoculation to and incubation on a Mueller-Hinton oxacillin screen plate and 
then confirmed using an “in-house” polymerase chain reaction assay to detect the mecA 
gene.    
No pre-selection criteria were used that would favor the inclusion or exclusion of 
organisms with specific susceptibilities to the various antimicrobial agents tested.  Care 
was taken to ensure that duplicate isolates from the same patient were excluded. 
American Type Culture Collection (ATCC) strains for Methicillin-susceptible 
Staphylococcus aureus (MSSA) (ATCC 29213 and ATCC 25923), Methicillin-resistant 
Staphylococcus aureus (MRSA) (ATCC 43300), S. pneumoniae (ATCC 49619), H. 
influenzae (ATCC 49427), E. coli (ATCC 25922), and P. aeruginosa (ATCC 27853) 
were obtained from the American Type Cultures Collection (Rocville, MD).  ATCC 
strains were used as controls for susceptibility testing and were tested each time a 
susceptibility test was performed. 
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2.1.2 Storage of the Bacterial Isolates 
Staphylococcus spp., P. aeruginosa, and E. coli isolates were streaked for isolated 
colonies on Tryptic Soy Agar (TSA) plates (in house) and incubated in O2 at 35 to 37°C 
for 18 to 24 hours. S. pneumoniae isolates were streaked for isolated colonies on TSA 
plates containing 5% sheep red blood cells (SRBCs) (Oxoid, Ryegate, MT) and incubated 
in CO2 at 35 to 37°C for 18 to 24 hours.  H. influenzae isolates were streaked for isolated 
colonies on Chocolate agar plates (PML Microbiologicals, Winnipeg, MB) and incubated 
in CO2 at 35 to 37°C for approximately 24 hours [64].  Following incubation, colonies 
were inoculated using a sterile wooden applicator stick into 1.2 ml Corning cryovials 
containing 0.5 ml of skim milk.  The vials were stored at -70°C. 
2.2 Susceptibility Testing 
 The antimicrobial agents used for in vitro experiments were obtained either in 
powdered form or in solution.  Those antimicrobials obtained in powdered form were 
diluted in accordance to the manufacturer’s recommendations.  Sources of antimicrobial 
agents were as follows: 
Alexidine (solution)  – Bausch and Lomb Pharmaceuticals Inc., Rochester, NY, U.S.A.; 
Benzalkonium chloride (BAK) (solution) – Allergan Inc., Irvine, CA, U.S.A.; 
Gatifloxacin (powder) – Bristol Myers Squibb, Montreal, QC, Canada; 
Gemifloxacin (powder) – Glaxo Smith Kline Pharmaceuticals, Collegeville, PA, U.S.A.; 
Oscient Pharmaceuticals, Waltham, MA, U.S.A.; 
Levofloxacin (solution) – Janssen Ortho, Toronto, ON, Canada; 
Moxifloxacin (powder) – Bayer Pharmaceutical, Toronto, ON, Canada; 
Tigecycline (powder) – Wyeth Pharmaceuticals, Collegeville, PA, U.S.A; 
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Vigamox (commercial solution) – Alcon, Fort Worth, TX, U.S.A.; 
Zymar (commercial solution) – Allergan Inc., Irvine, CA, U.S.A. 
2.2.1  Broth Microdilution 
The broth microdilution method was used to determine minimum inhibitory 
concentration (MIC) values for all organisms in accordance with the Clinical Laboratory 
and Standards Institute (CLSI) guidelines [65]. To prepare 96-well microtitre panels 
(Sarstedt, Newton, NC) used for broth microdilution testing, 100 µl of appropriate broth 
was added to each well of columns 2 to 12.  Mueller-Hinton Broth (MHB) (Becton 
Dickinson, Sparks, MD) was used for Staphylococcus spp., E. coli, and P. aeruginosa; 
Todd-Hewitt Broth (THB) (Becton Dickinson, Sparks, MD) was used for S. pneumoniae; 
and Pluronic Inoculum water for H. influenzae.  Antimicrobial agent was serially diluted 
down the panel with the wells of column 1 containing the highest concentration of drug 
and the wells of column 11 the lowest concentration of drug.  The wells of column 12 
were used as a growth control and, therefore, did not receive any drug. 
Organisms were subcultured onto TSA + 5% SRBC plates and incubated under 
appropriate conditions for 18 to 24 hours at 35 to 37°C: S. pneumoniae and H. influenzae 
in 5% CO2, Staphylococcus spp. E. coli, and P. aeruginosa in O2.  Following incubation, 
each organism was standardized to a 0.5 McFarland (∼1.0 X 108 CFU/ml) using a 
colorimeter.  The bacterial suspensions were then diluted 1/100 with the appropriate 
broth medium (as above except H. influenzae is diluted with Brain Heart Infusion plus 
5% fildes (Becton Dickinson, Sparks, MD)) to give a bacterial load of approximately 1.0 
X 106 CFU/ml.  One hundred µl of the bacterial suspension was then added to each well 
in the microtitre panel resulting in a final bacterial concentration of approximately 1.0 x 
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105 CFU/ml.  The microtitre panels were then incubated under the appropriate conditions 
(as above) for 18 to 24 hours at 35 to 37°C.  Following incubation, the lowest drug 
concentration at which there was no visible growth of organism was recorded as the MIC. 
 A sample of each bacterial suspension was plated onto fresh TSA + 5% SRBC 
plates and incubated in ambient air at 35 to 37°C for 18 to 24 hours to ensure the purity 
of the bacterial suspensions.  The wells in column 12 (growth control) were also 
examined to ensure organism viability.  The appropriate ATCC strain(s) was/were used 
in each assay as a control to confirm the validity of the results based on the current CLSI 
breakpoints for each ATCC strain.  
2.3 Mutant Prevention Concentration (MPC) 
 Dong et al. first defined the MPC concept and initial MPC method in 1999 [69].   
The laboratory of Dr. J. Blondeau (Royal University Hospital, Saskatoon, SK) has since 
described MPC testing protocols for the following organisms:  S. pneumoniae [68], S. 
aureus [72], Staphylococcus intermedius, E. coli [73, 74], P. aeruginosa [74, 75], H. 
influenzae [76], Citrobacter freundii [74], Actinobacillus  pleuropneumoniae, 
Enterobacter cloacae [74], Klebsiella pneumoniae [74], Pasteurella multocida, 
Histophilus somni, and Mannheimia haemolytica [77]. 
2.3.1 Inoculum Preparation 
 Preparation of the bacterial suspension required for MPC testing is tedious and 
time-consuming and different protocols are required for different bacterial organisms.  
The protocol is highly dependent upon the fastidiousness of the organism; the more 
fastidious an organism the more involved the protocol.  The challenge in MPC testing is 
to generate bacterial suspensions of ≥109 CFUs.  In order to achieve such high bacterial 
  33 
densities, confluent bacterial growth from several agar plates is transferred into the 
appropriate broth medium and incubated for the appropriate time at the appropriate 
conditions.  There are currently two methods available to determine the MPC value of a 
particular microorganism to a particular antimicrobial compound:  the traditional agar 
dilution method and the novel microbroth dilution method.  Both methods were 
developed in the laboratory of Dr. J. Blondeau, Royal University Hospital, Saskatoon, SK.  
2.3.2 Traditional MPC testing:  Agar Dilution Method 
 The traditional MPC testing method is the agar dilution method.  Bacterial 
isolates were streaked from thawed skim milk onto TSA + 5% SRBC plates using a 
sterile wooden stick and incubated under ambient conditions at 35 to 37°C for 18 to 24 
hours.  Following incubation, growth from the original plate was transferred to fresh TSA 
+ 5% SRBC plates using a sterile swab.  The entire surface of the fresh plates was 
inoculated to ensure confluent bacterial growth.  The number of plates inoculated was 
dependent on the fastidiousness of the organism; S. pneumoniae was inoculated onto 8 
plates and Staphylococcus spp. onto 3 plates.  Once the fresh TSA + 5% SRBC plates 
were inoculated they were incubated under the appropriate conditions for a further 18 to 
24 hours at 35 to 37°C; S. pneumoniae was incubated in 5% CO2 and Staphylococcus spp. 
in O2. 
 After overnight incubation, the plates containing confluent bacterial growth were 
transferred, using a sterile swab, into a defined volume of appropriate broth; S. 
pneumoniae into 500 ml of THB and Staphylococcus spp. into 100 ml of MHB.  
Following the transfer of organism into the appropriate broth, another overnight 
incubation of 18 to 24 hours was required for the proliferation of the bacterial cells.  S. 
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pneumoniae is a fastidious organism and requires a centrifugation step in order to achieve 
the large bacterial densities required for MPC testing.  To concentrate the bacterial load 
of S. pneumoniae, cultures were centrifuged at 8,000 rpm for 20 minutes at 4°C and then 
re-suspended in 3 ml of fresh THB. To ensure that the cellular concentration of each 
isolate was of sufficient density (≥109 CFUs), an absorbance reading was taken using a 
spectrophotometer.  For S. pneumoniae an absorbance reading of ≥0.3 at a wavelength of 
600 nm was used to estimate a cellular density of ≥109 CFU/ml and for Staphylococcus 
spp. an absorbance reading of ≥1.0 at a wavelength of 600 nm was used to estimate a 
cellular density of ≥1010 CFU/ml.  Viable counts were performed on the high-density 
bacterial cultures to ensure that a concentration of ≥109 CFU/ml existed.  A purity plate 
was prepared using a sterile stick to streak out the high-density bacterial suspension onto 
a TSA + 5% SRBC plate.  The purity plates were incubated under the appropriate 
conditions (O2 for Staphylococcus spp. and CO2 for S. pneumoniae) for 18 to 24 hours at 
35 to 37°C and examined for contaminants. 
 For each experiment, agar plates were prepared containing doubling dilutions of 
antimicrobial agent.  In most cases seven plates were prepared for each isolate, each with 
a different concentration of antimicrobial agent.  The range of drug concentrations tested 
included the measured MIC value of each isolate, one doubling dilution below the MIC 
value, and a minimum of five doubling dilutions above the MIC value.  To create the agar 
dilution plates, the defined amount of antimicrobial agent was added to liquid TSA + 5% 
SRBC agar was also added to agar on which S. pneumoniae was to be grown.  The agar 
was then poured into plastic petri plates (Fisher Scientific, USA) and allowed to solidify 
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overnight.  Plates were kept at room temperature and used within 2 to 3 days of their 
preparation.  
 After taking absorbance readings and making certain that the bacterial cultures 
had cellular densities of ≥109 CFU/ml, aliquots were applied to the prepared TSA + 5% 
SRBC plates containing differing concentrations of the antimicrobial agent of interest.  
For S. pneumoniae, aliquots of 200 µl were applied to the drug plates and for 
Staphylococcus spp. aliquots of 100 µl were applied to the drug plates.  An appropriate 
and fully susceptible ATCC strain was included in each experiment: ATCC 49619 for S. 
pneumoniae and ATCC 29213 or ATCC 25923 for Staphylococcus spp.  Following 
inoculation, plates were incubated under the appropriate conditions (ambient air for 
Staphylococcus spp. and 5% CO2 for S. pneumoniae) for 18 to 24 hours at 35 to 37°C and 
then screened for growth.  The plates were then incubated for a further 18 to 24 hours and 
re-screened for growth.  The MPC was recorded as the lowest concentration of 
antimicrobial agent that allowed no visible bacterial growth. 
 In certain cases, a faint haze caused by the high-density inoculum was seen on 
plates.  This faint haze rendered it difficult to interpret whether these plates were positive 
for growth; additional steps were therefore used to determine accurate MPC values.  
Potential growth was collected using a sterile swab and was transferred to a prepared 
TSA + 5% SRBC plate containing the same antimicrobial concentration as the plate in 
question.  These fresh drug plates inoculated with potentially viable cells were then 
incubated for 18 to 24 hours in ambient air (5% CO2 for S. pneumoniae) at 35 to 37°C 
and screened for growth.  The MPC was recorded as the lowest drug concentration 
preventing visible growth.    
  36 
2.3.3 Modified MPC testing: Microbroth Dilution Method 
I developed a novel method for MPC testing: the modified microbroth dilution 
method [78].  A 96-well microtitre panel is used in this method instead of agar plates 
containing doubling dilutions of antimicrobial agent.  The first step in this method is to 
generate a bacterial suspension that has a cellular density of ≥109 CFU/ml. The protocol 
for generating such a high-density inoculum is the same as that used in the traditional 
MPC method. Bacterial isolates were streaked from thawed skim milk onto TSA + 5% 
SRBC plates using a sterile wooden stick and incubated under ambient conditions at 35 to 
37°C for 18 to 24 hours.  Following incubation, growth from the original plate was 
transferred to fresh TSA + 5% SRBC plates using a sterile swab.  The entire surface of 
the fresh plates was inoculated to ensure confluent bacterial growth.  The number of 
plates inoculated was dependent on the fastidiousness of the organism; S. pneumoniae 
was inoculated onto 8 plates and Staphylococcus spp. onto 3 plates.  Once the fresh TSA 
+ 5% SRBC plates were inoculated they were incubated under the appropriate conditions 
for a further 18 to 24 hours at 35 to 37°C; S. pneumoniae was incubated in 5% CO2 and 
Staphylococcus spp. in O2. 
 After overnight incubation, the plates containing confluent bacterial growth were 
transferred, using a sterile swab, into 10 ml of broth; S. pneumoniae into THB and 
Staphylococcus spp. into MHB. Following the transfer of organism into broth, an 
incubation period of 2 hours at 35 to 37°C under ambient conditions was required for the 
proliferation of the bacterial cells.  At this point viable counts were performed on the 
high-density bacterial cultures to ensure that a concentration of ≥109 CFU/ml was present 
and each isolate was streaked onto a TSA + 5% SRBC plate using a sterile wooden 
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applicator stick.  The TSA + 5% SRBC plate was incubated in ambient air for 18 to 24 
hours at 35 to 37°C and then screened to ensure each isolate was pure.  An appropriate 
and fully susceptible ATCC strain was included in each experiment: ATCC 49619 for S. 
pneumoniae and ATCC 29213 or ATCC 25923 for Staphylococcus spp.  
One hundred µl of each high-density bacterial suspension was added to all wells 
in a single row in a 96-well microtitre panel prepared with doubling dilutions of antibiotic.  
To prepare 96-well microtitre panels, 100 µl of the appropriate broth (THB for S. 
pneumoniae and MHB for Staphylococcus spp.) was added to each well in columns 2 to 
12.  Antimicrobial agent was serially diluted down the 96-well microtitrepanel with the 
wells of column 1 containing the highest concentration of drug and the wells of column 
11 the lowest concentration of drug.  The wells of column 12 were used as a growth 
control and therefore did not receive any drug.  The final bacterial concentration in each 
well is diluted 1/10 from the concentration of the initial stock tube.  For example, if the 
concentration of the initial bacterial suspension was 1.0 X 1010 CFU/ml, the final 
bacterial burden would be approximately 1.0 X 109 CFUs following the addition of 100 
µl of bacterial suspension to each well.  After adding 100 µl of each bacterial suspension, 
the microtitre panels were incubated in ambient air (5% CO2 for S. pneumoniae) for 18 to 
24 hours at 35 to 37°C. 
Following incubation the microtitre panels are screened for growth and the lowest 
drug concentration showing no visible growth is the MPC.  In some instances the wells 
were too cloudy to read due to the very high cellular concentration (debris) and additional 
steps were required to determine accurate MPC values.  A sterile wooden applicator stick 
was placed into each well that was difficult to read and was subsequently used to streak a 
  38 
TSA + 5% SRBC plate containing the corresponding concentration of antimicrobial agent.  
In order for this additional step to be completed, agar dilution plates must be prepared as 
detailed in the traditional MPC method.  The TSA + 5% SRBC plates are incubated in 
ambient air for 18 to 24 hours at 35 to 37°C.  
2.3.4 Viable Counts 
 When completing traditional MPC testing, viable counts were performed, after 
measuring absorbance values, on isolates with the highest and lowest absorbance 
readings.  The initial bacterial suspensions were diluted to 10-7, 10-8, and 10-9 and 100 µl 
of each dilution were plated onto triplicate TSA + 5% SRBC plates.  The plates were 
incubated in ambient air for 24 hours at 35 to 37°C.  Following incubation, colony counts 
were performed on each plate and calculations completed to determine the bacterial 
concentration in CFU/ml.  When using the modified microbroth dilution MPC testing 
method, viable counts were performed on each isolate using the same method. 
2.3.5 E-test 
 E-test was used as a potential method of determining MPC values for S. aureus 
isolates.  A bacterial suspension with a cellular density of ≥1010 CFU/ml is generated by 
streaking bacterial isolates from thawed skim milk onto TSA + 5% SRBC plates using a 
sterile wooden stick and incubated under ambient conditions at 35 to 37°C for 18 to 24 
hours.  Following incubation, growth from the original plate was transferred to 3 fresh 
TSA + 5% SRBC plates using a sterile swab.  The entire surface of the fresh plates was 
inoculated to ensure confluent bacterial growth. Once the fresh TSA + 5% SRBC plates 
were inoculated they were incubated in ambient air at 35 to 37°C for a further 18 to 24 
hours. 
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 After overnight incubation, the plates containing confluent bacterial growth were 
transferred, using a sterile swab, into 10 ml of MHB and incubated for 2 hours in ambient 
air at 35 to 37°C.  At this point viable counts were performed on the high-density 
bacterial cultures to ensure that a concentration of ≥1010 CFU/ml was present and each 
isolate was streaked onto a TSA + 5% SRBC plate using a sterile wooden applicator stick.  
The TSA + 5% SRBC plate was incubated in ambient air for 18 to 24 hours at 35 to 37°C 
and then screened to ensure each isolate was pure. A fully susceptible S. aureus control 
strain (ATCC 29213) was included in each experiment. 
 One hundred µl of each high-density bacterial suspension was added to MH agar 
plates and spread using a sterile cell spreader (Fisher Scientific, U.S.A.).  E-test strips 
(Ab Biodisk, U.S.A.) were then added to the centre of the inoculated MH agar plate using 
sterile forceps and incubated in ambient air for 18 to 24 hours at 35 to 37°C.  The plates 
were read as described by the E-test manufacturer and the lowest concentration inhibiting 
growth was taken as the MPC. 
2.4 Development of New Media for MPC Testing of Tigecycline 
 The laboratory of Dr. J. Blondeau (Royal University Hospital, Saskatoon, SK) 
developed a novel formulation of Todd-Hewitt Broth for MPC testing of the 
antimicrobial agent tigecycline:  solidified Todd-Hewitt Broth (sTHB).  To our 
knowledge we are the first to use sTHB for susceptibility testing [79-81].  Solidified 
Todd-Hewitt Broth was prepared by adding 1.5% granulated agar (Becton Dickinson, 
Sparks, MD) to THB powder, dissolved in the appropriate volume of water (as described 
by the manufacturer), and autoclaving for 15 minutes at 121°C.  Following removal from 
the autoclave, the liquid agar was cooled to 55°C in a water bath.  Antimicrobial agent 
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was added to the liquid agar, stirred and then approximately 20 ml was poured into sterile 
petri plates and allowed to solidify.  ATCC strains were inoculated to these plates, 
incubated as described, and then screened to ensure organism growth.    
2.5 Time - Kill Experiments 
 Bacterial isolates were streaked from thawed skim milk onto TSA + 5% SRBC 
plates using a sterile wooden stick and incubated under ambient conditions at 35 to 37°C 
for 18 to 24 hours.  Following incubation, growth from the original plate was transferred 
to fresh TSA + 5% SRBC plates using a sterile swab.  The entire surface of the fresh 
plates was inoculated to ensure confluent bacterial growth; S. pneumoniae was inoculated 
onto 6 plates while Staphylococcus spp. and P. aeruginosa were inoculated onto one 
plate.  Once the fresh TSA + 5% SRBC plates were inoculated they were incubated under 
the appropriate conditions for a further 18 to 24 hours at 35 to 37°C: Staphylococcus spp. 
and P. aeruginosa were incubated in ambient air and S. pneumoniae was incubated in 5% 
CO2.   
 Following incubation, bacterial growth from the plates was transferred with a 
sterile swab to 10 ml of broth and incubated for 2 hours under the appropriate conditions.  
For Staphylococcus spp. and P. aeruginosa, half a plate of bacterial growth was 
transferred to MHB and incubated in ambient air.  Six full plates of bacterial growth were 
transferred to THB and incubated in 5% CO2 for S. pneumoniae.  A viable count of the 
bacterial suspension was taken and corresponded to a bacterial density (CFU/ml) of 109, 
109, and 107 for Staphylococcus spp., P. aeruginosa, and S. pneumoniae respectively.  To 
achieve an inoculum concentration of 105 CFU/ml, the 10 ml suspensions were serially 
diluted; 700 µl was removed and added to 7 ml of fresh broth.  At this point antimicrobial 
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agent was added to the 105 CFU/ml dilutions at concentrations corresponding to the MIC, 
2 x MIC, and 4 x MIC.  The 105 CFU/ml dilutions, containing antimicrobial agent, were 
vortexed and incubated under the appropriate conditions as described for 180 minutes.  
This was done in triplicate. 
 One hundred µl aliquots of the 105 CFU/ml dilutions were taken at 0, 15, 30, 45, 
60, 75, 90, 120, and 180 minutes after the addition of antimicrobial agent.  The aliquots 
were diluted 1/10 in the appropriate broth and applied to TSA + 5% SRBC plates in 
triplicate and incubated at 35 to 37°C for 18 to 24 hours under the appropriate conditions.  
Following incubation, the number of colonies on each plate was recorded and the log10-
reduction (percent kill) of viable cells was calculated.   The aliquots were diluted 1/10 so 
that viable counts had a countable number of colonies (20 – 200). For some experiments 
aliquots were taken at 0, 0.5, 1, 2, 3, 4, 5, 10, and 15 minutes after the addition of 
antimicrobial agent and for other experiments at 0, 5, 10, 15, 20, 25, 30, 60, 120, and 180 
minutes after the addition of antimicrobial agent. 
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3.0 RESULTS 
3.1 Methods to Simplify MPC Testing 
 3.1.1 Traditional MPC Testing 
The traditional MPC testing method is the agar dilution method.  Mutant 
prevention concentration values were experimentally determined, using the agar dilution 
method, for Streptococcus pneumoniae and Methicillin-susceptible Staphylococcus 
aureus (MSSA) ATCC control strains (ATCC 49619 and ATCC 29213 respectively) 
against gatifloxacin and moxifloxacin.  The traditional MPC values for S. pneumoniae 
(ATCC 49619) against gatifloxacin and moxifloxacin were both 0.5 µg/ml (Table 
3.1.1.1).  The traditional MPC values for MSSA (ATCC 29213) against gatifloxacin and 
moxifloxacin were 8 µg/ml and 4 µg/ml respectively (Table 3.1.1.1).   
 3.1.2 Modified MPC Testing 
 The modified MPC testing method is the microbroth dilution method.  We 
developed this novel method in our laboratory and to our knowledge we are the only lab 
to use this method [78].  Mutant prevention concentration values were experimentally 
determined, using the microbroth dilution MPC method, for S. pneumoniae (ATCC 
49619) and MSSA (ATCC 29213) control strains against gatifloxacin and moxifloxacin.  
The microbroth dilution MPC values for S. pneumoniae (ATCC 49619) against 
gatifloxacin and moxifloxacin were both 0.5 µg/ml (Table 3.1.1.1).  The microbroth 
dilution MPC values for MSSA (ATCC 29213) against gatifloxacin and moxifloxacin 
were ≥8 µg/ml and >2 µg/ml respectively (Table 3.1.1.1).  Comparison of the MPC 
values generated by the traditional- and microbroth dilution- MPC methods provided 




  MPC values (µg/ml) 
  S. pneumoniae (ATCC 49619) MSSA (ATCC 29213) 
Drug Traditional Method
a Microbroth Dilution Method Traditional Method
a Microbroth Dilution Method 
Gatifloxacin 0.5 0.5 8 ≥8 
Moxifloxacin 0.5 0.5 4 >2 
 
Table 3.1.1.1: Comparison of the in vitro MPC values (µg/ml) generated using the traditional MPC methoda and the microbroth dilution 
MPC method. 
a Agar Dilution Method 
MPC = Mutant Prevention Concentration; MSSA = Methicillin-susceptible Staphylococcus aureus 
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a reliable method for determining MPC values.  It is important to mention that when 
using the microbroth dilution MPC method for the testing of S. pneumoniae, the highest 
bacterial density achieved was 107 CFU/ml because of the fastidiousness of S. 
pneumoniae.  Regardless of the lower bacterial density, results were still consistent with 
those generated with higher bacterial densities (using the traditional MPC method). 
  3.1.2.1 Inhibitory Values at Different Bacterial Concentrations 
 Antimicrobial susceptibility testing was performed using the microbroth dilution 
MPC method with bacterial concentrations ranging from 101 to 109 CFU/ml (101 to 107 
CFU/ml for S. pneumoniae) for S. pneumoniae (ATCC 49619) and MSSA (ATCC 29213) 
against gatifloxacin and moxifloxacin.  The results of these experiments are summarized 
in Table 3.1.2.1.1.  It is evident that as the bacterial burden increases so does the 
antimicrobial concentration required to inhibit growth.  For MSSA (ATCC 29213), the 
largest increase in antimicrobial inhibitory concentration occurs when the bacterial 
burden increases from 106 to 107 CFU/ml; from 0.125 µg/ml to 4 µg/ml for gatifloxacin 
and from 0.5 µg/ml to >2 µg/ml for moxifloxacin.  For S. pneumoniae (ATCC 49619), 
the antimicrobial inhibitory concentration increases steadily with increasing bacterial 
densities, with no large increase seen between any two consecutive bacterial 
concentrations. 
 The MIC and MPC values, as determined by the microbroth dilution MPC 
method, were compared with MIC and MPC values determined by the traditional MIC 
and MPC methods.  The traditional MIC method was the microbroth dilution method 
with 105 CFU/ml being achieved using a 0.5 McFarland standard.  The comparison of 
these values is seen in Table 3.1.2.1.2 and also visually in Figures 3.1.2.1.1 and 3.1.2.1.2.
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  Inhibitory Concentrations (µg/ml) 
Gatifloxacin Moxifloxacin Bacterial 
Concentration 
(CFU/ml) S. pneumoniae (ATCC 49619) MSSA (ATCC 29213) S. pneumoniae (ATCC 49619) MSSA (ATCC 29213) 
101 0.125 0.063 0.063 0.016 
102 0.125 0.063 0.063 0.016 
103 0.125 0.063 0.125 0.031 
104 0.125 0.063 0.125 0.031 
105 0.25 0.125 0.125 0.031 
106 0.25 0.125 0.25 0.5 
107 0.5 4 0.5 >2 
108  ≥8  >2 
109  ≥8  >2 
 
Table 3.1.2.1.1: Inhibitory concentrations (µg/ml) for S. pneumoniae (ATCC 49619) and MSSA (ATCC 29213) against gatifloxacin and 
moxifloxacin at different bacterial concentrations. 
MSSA = Methicillin-susceptible Staphylococcus aureus 
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3.1.3 E-test   
 The E-test method is commonly used in clinical laboratories as a fast and simple 
way of determining MIC values; we looked at the E-test as a possible method for 
determining MPC values.  E-test strips have a calibrated gradient of antimicrobial agent 
and when placed on agar plates with standardized concentrations of bacteria, the 
inhibitory antimicrobial concentration can be determined by establishing at what 
antimicrobial concentration bacterial colonies cross the calibrated strip.  Traditionally E-
test strips are used to determine MIC values, and as such a standardized bacterial 
inoculum of 105 CFUs is applied confluently to the agar plates. We placed gatifloxacin E-
test strips onto plates containing confluent growth of ≥109 CFUs in an attempt to 
determine the MPC values for the MSSA ATCC control strain (ATCC 29213) against 
gatifloxacin.   
 Using gatifloxacin E-test strips, the concentration required to inhibit the growth of 
MSSA (ATCC 29213) at a bacterial concentration of 109 CFUs was experimentally 
determined to be 0.25 µg/ml in two separate assays.  The MPC values for MSSA (ATCC 
29213) against gatifloxacin, determined using both the traditional and microbroth dilution 
MPC methods, were 8 µg/ml and ≥8 µg/ml respectively.  Therefore, the E-test 
determined MPC values for MSSA (ATCC 29213) against gatifloxacin are not consistent 
with MPC values determined using either the traditional- or modified- MPC method. 
 In further experiments, we determined the inhibitory concentration values (µg/ml) 
of gatifloxacin for different bacterial concentrations (i.e. 101 to 109 CFU/ml) of MSSA 
(ATCC 29213) using gatifloxacin E-test strips.  Bacterial suspensions of MSSA (ATCC 
29213) with cellular concentrations of 101, 102, 103, 104, 105, 106, 107, 108, and 109  
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  S. pneumoniae (ATCC 49619) 
  Traditional Method
a Microbroth Dilution Method 
Drug MIC (µg/ml) MPC (µg/ml) MIC (µg/ml) MPC (µg/ml) 
Gatifloxacin 0.25 0.5 0.25 0.5 
Moxifloxacin 0.125 0.5 0.063 0.5 
  MSSA (ATCC 29213) 
Gatifloxacin 0.125 8 0.125 ≥8 
Moxifloxacin 0.031 4 0.031 >2 
 
Table 3.1.2.1.2: Comparative MIC and MPC values (µg/ml) as determined by the traditional methoda and the microbroth dilution method 
for S. pneumoniae (ATCC 49619) and MSSA (ATCC 29213) against gatifloxacin and moxifloxacin. 
a Agar Dilution Method 





Figure 3.1.2.1.1:  Comparative MIC and MPC values (µg/ml) as determined by the traditional methoda and the microbroth dilution 
method for S. pneumoniae (ATCC 49619) against gatifloxacin and moxifloxacin. 
a Agar Dilution Method 




Figure 3.1.2.1.2:  Comparative MIC and MPC values (µg/ml) as determined by the traditional methoda and the microbroth dilution 
method for MSSA (ATCC 29213) against gatifloxacin and moxifloxacin. 
a Agar Dilution Method 
MIC = Minimum Inhibitory Concentration; MPC = Mutant Prevention Concentration; MSSA = Methicillin-susceptible 
Staphylococcus aureus  
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 CFU/ml were applied to agar plates and a gatifloxacin E-test strip was subsequently 
added before incubation for 18 to 24 hours under appropriate conditions.  The assay was 
performed in duplicate.  To ensure that the appropriate concentration of bacteria was 
added to each agar plate, a colony count of viable cells was performed on each bacterial 
concentration.  When 100 µl of organism is added to the agar plate, the actual bacterial 
concentration on the plate is 1:10 the initial concentration in the tube (and the 
concentration of the viable count).  For example, if 100 µl of a bacterial suspension of 
109 CFUs is added to the plate, the actual bacterial suspension of that plate will be 108 
CFUs.  Therefore in order to determine the MPC of a bacterial suspension of 109 CFUs, 
an initial bacterial suspension of 1010 CFUs is required.  
 In the first assay, the resulting inhibitory concentrations (µg/ml) were 0.064, 
0.064, 0.094, 0.094, 0.125, 0.19, and 0.25 for bacterial burdens of 103, 104, 105, 106, 107, 
108, and 109 CFUs respectively.  Similar results were observed in the second assay with 
inhibitory concentrations (µg/ml) of 0.064, 0.064, 0.064, 0.125, 0.125, 0.19, and 0.25 for 
bacterial burdens of 103, 104, 105, 106, 107, 108, and 109 CFUs respectively (Figure 
3.1.3.1c - i).  There were too few colonies to determine inhibitory concentrations with the 
E-test strips at bacterial burdens of 101 and 102 CFUs (Figure 3.1.3.1a and b).  When 
these inhibitory concentrations were compared to the inhibitory concentrations 
determined with the microbroth dilution method, there was a noticeable discrepancy in 
values (Table 3.1.3.1 and Table 3.1.3.2).  The inhibitory values were similar for both 
methods until higher bacterial burdens were used (i.e. 107 to 109 CFUs) indicating that 














Figure 3.1.3.1: Photos of E-test strips containing a concentration gradient of gatifloxacin on plates with different bacterial 
concentrations of MSSA (ATCC 29213). 
MSSA = Methicillin-susceptible Staphylococcus aureus 
101 a b 












Inhibitory Concentrations (µg/ml) Bacterial 
Concentration 
(CFUs) E-test Method Microbroth Dilution Method 
Viable count of initial tube 
(CFU/ml) 
101 too few colonies 0.063 4.23 x 102 
102 too few colonies 0.063 3.73 x 103 
103 0.064 0.063 2.90 x 104 
104 0.064 0.063 3.63 x 105 
105 0.094 0.125 5.10 x 106 
106 0.094 0.125 5.37 x 107 
107 0.125 4 4.93 x 108 
108 0.19 ≥8 6.53 x 109 
109 0.25 ≥8 6.97 x 1010 
 
Table 3.1.3.1: Comparative inhibitory concentrations (µg/ml) for MSSA (ATCC 29213) against gatifloxacin determined using two methods: 
E-test method and microbroth dilution method.  First assay. 
 
Inhibitory Concentrations (µg/ml) Bacterial 
Concentration 
(CFUs) E-test Method Microbroth Dilution Method 
Viable count of initial tube 
(CFU/ml) 
101 too few colonies 0.063 2.73 x 102 
102 too few colonies 0.063 2.73 x 103 
103 0.064 0.063 2.70 x 104 
104 0.064 0.063 2.93 x 105 
105 0.064 0.125 3.47 x 106 
106 0.125 0.125 4.30 x 107 
107 0.125 4 5.00 x 108 
108 0.19 ≥8 5.63 x 109 
109 0.25 ≥8 6.00 x 1010 
 
Table 3.1.3.2: Comparative inhibitory concentrations (µg/ml) for MSSA (ATCC 29213) against gatifloxacin determined using two methods: 
E-test method and microbroth dilution method.  Second assay. 
  53 
3.1.4 Linear Regression 
 To determine whether it would be possible to extrapolate MPC values from the 
MIC values for specific bacterial pathogens against specific antimicrobial agents, we 
calculated the correlation coefficients (r2) for five bacterial species against several 
flouroquinolones and for S. pneumoniae against several fluoroquinolones and three 
macrolides [82].  Linear regression was used to calculate the r2 values.  Data were from 
published and unpublished studies of clinical isolates.  The r2 values, shown in Table 
3.1.4.1, are low (below 0.5) for fluoroquinolones with Escherichia coli, Klebsiella 
pneumoniae, Pseudomonas aeruginosa, S. aureus, and S. pneumoniae (an exception was 
levofloxacin with K. pneumoniae [r2 = 0.7]).  The r2 values for the three macrolides with 
S. pneumoniae were slightly above 0.5.  The low r2 values indicate that it is not possible 
to extrapolate a MPC value from a MIC value using simple linear regression. 
3.2 The Impact of Media on MPC Testing 
 Whilst conducting MPC testing (traditional method) of tigecycline against clinical 
isolates of S. pneumoniae we measured MPC values that were unexpectedly higher than 
the corresponding MIC values for each isolate.  The MPC results for most bacteria-
antimicrobial agent combinations are generally 2 to 8 fold greater than the corresponding 
MIC results [83].  However, in our testing of tigecycline against S. pneumoniae we 
measured MPC values that were ≥512 fold higher than the corresponding MIC values.  
We designed several experiments to determine whether the media, specifically blood in 
the media, was having an impact on MPC results.






























Table 3.1.4.1: Relationship between MICs and MPCs. 
MIC = Minimum Inhibitory Concentration; MPC = Mutant Prevention Concentration; r2 = 
correlational coefficient [82]
Bacterial species Compound tested r2 for MPC/MIC No. of isolates 
E. coli Garenoxacin 0.26 44 
 Gatifloxacin 0.03 44 
 Gemifloxacin 0.1 44 
 Levofloxacin 0.02 43 
 Moxifloxacin 0.03 40 
    
K. pneumoniae Garenoxacin 0.09 39 
 Gatifloxacin 0.34 40 
 Gemifloxacin 0.15 39 
 Levofloxacin 0.7 41 
 Moxifloxacin 0.18 40 
    
P. aeruginosa Ciprofloxacin 0.41 151 
 Levofloxacin 0.43 151 
    
S. aureus Ciprofloxacin 0.11 21 
 Garenoxacin 0.08 82 
 Gatifloxacin 0.04 218 
 Gemifloxacin 0.05 218 
 Levofloxacin 0.18 220 
 Moxifloxacin 0.08 219 
    
S. pneumoniae Garenoxacin 0.31 524 
 Gatifloxacin 0.28 516 
 Gemifloxacin 0.29 495 
 Levofloxacin 0.44 528 
 Moxifloxacin 0.17 523 
 Azithromycin 0.58 499 
 Erythromycin 0.67 293 
  Clarithromycin 0.67 278 
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3.2.1 Streptococcus pneumoniae 
 Using traditional methods, we measured the MIC and MPC values for tigecycline 
against 47 clinical isolates of S. pneumoniae.  Traditional methods for MIC and MPC 
testing were the microbroth dilution method and the agar dilution method using tryptic 
soy agar (TSA) with 5% sheep red blood cells (SRBCs) respectively.  The MIC50 and 
MPC50 values were defined as the lowest drug concentration preventing growth of 50% 
of bacterial strains while the MIC90 and MPC90 were defined as the lowest drug 
concentration preventing growth of 90% of bacterial strains. The MIC50, MIC90 and MIC 
range values (µg/ml) were 0.016, 0.031, and ≤0.008 – 0.125 respectively.  The MPC50, 
MPC90, and MPC range values (µg/ml) were 8, ≥16, and ≤1 - ≥16 respectively.  To 
investigate whether the presence of blood in the test media was influencing MPC results, 
we developed a novel formulation of a medium on which S. pneumoniae could grow 
without blood.  The new test medium was developed in our lab by solidifying Todd-
Hewitt Broth with 1.5% agarose; these plates were called solidified Todd-Hewitt Broth 
(sTHB) plates [80, 81].  
 MPC testing of tigecycline against the same 47 clinical isolates of S. pneumoniae 
was completed using sTHB plates (without blood) and the resulting MPC50, MPC90, and 
MPC range values (µg/ml) were 0.063, 0.5, and 0.063 – 0.5 respectively.  These values 
were considerably lower than those measured using TSA + 5% SRBCs.  In fact, the 
MPC90 values measured using sTHB (without blood) were only 2 fold higher than the 
MIC90 values of the same isolates.  Recall, the MPC90 values measured using TSA + 5% 
SRBCs were ≥512 fold higher than the corresponding MIC90 values.  Additional 
experiments were performed to determine whether the significantly lower MPC values 
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observed when using sTHB over TSA + 5% SRBCs were due to the absence of blood in 
sTHB or because of the sTHB itself.  MPC testing was done with tigecycline against the 
47 clinical isolates of S. pneumoniae using sTHB + 5% SRBCs.  The resulting MPC50, 
MPC90, and MPC range values (µg/ml) using sTHB + 5% SRBCs were >8, >8, and 4 - ≥8 
respectively, indicating the presence of some type of interaction between blood and 
tigecycline in the testing of S. pneumoniae.  The results of all MPC and MIC testing are 
summarized in Table 3.2.1.1 and Figure 3.2.1.1. 
 3.2.2 Staphylococcus aureus      
 To investigate whether the presence of blood in the test media would influence 
MPC results for other organisms against tigecycline, MPC testing was done with 
tigecycline against clinical isolates of MSSA (n = 50) and MRSA (n = 50).  First we used 
traditional methods (microbroth dilution method for MIC and agar dilution method for 
MPC testing) to determine the MIC and MPC values of tigecycline against both MSSA 
and MRSA isolates.  Generally, when MPC testing is done with S. aureus isolates 
(MSSA and MRSA) TSA plates are created containing doubling dilutions of drug with no 
blood.  For these experiments we completed traditional MPC testing using TSA plates 
without blood and also TSA plates with 5% SRBCs.  We measured MIC50, MIC90, and 
MIC range values (µg/ml) of 0.063, 0.125, and 0.031 – 0.125 respectively for MSSA and 
0.125, 0.5, and 0.063 – 1 respectively for MRSA.  For MSSA isolates we measured 
MPC50, MPC90, and MPC range values (µg/ml) of 1, 2, and 1 – 4 respectively on TSA 
(no blood) compared to 0.5, 1, and 0.25 – 2 respectively on TSA + 5% SRBC.  For 
MRSA isolates the MPC50, MPC90, and MPC range values (µg/ml) on TSA (without 
blood) were 1, 4, and 0.5 – 8 respectively compared to 0.5, 4, and 0.5 – 4 respectively on
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Test Media MPC50a (µg/ml) MPC90b (µg/ml) MPC Range (µg/ml) 
TSA + 5% SRBC 8 ≥16 ≤1 - ≥16 
sTHB 0.063 0.5 0.063 - 0.5 
sTHB + 5% SRBC >8 >8 4 - ≥8 
  MIC50a (µg/ml) MIC90b (µg/ml) MIC Range (µg/ml) 
Microbroth Dilution 0.016 0.031 ≤0.008 - 0.125 
 
Table 3.2.1.1: Summary of MIC and MPC Results for tigecycline against 47 clinical isolates of S. pneumoniae measured using different 
media. 
a The drug concentration inhibiting 50% of isolates tested 
b The drug concentration inhibiting 90% of isolates tested 
MPC = Mutant Prevention Concentration; MIC = Minimum Inhibitory Concentration; TSA = tryptic soy agar; SRBC = sheep red 




Figure 3.2.1.1: Distribution values for 47 clinical isolates of S. pneumoniae against tigecycline. 
MPC = Mutant Prevention Concentration; MIC = Minimum Inhibitory Concentration; TSA = tryptic soy agar; SRBC = sheep red 
blood cells; sTHB = solidified Todd-Hewitt Broth 
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TSA + 5% SRBC (Table 3.2.2.1).   
The distribution of all MIC and MPC values for tigecycline against 50 clinical 
isolates of MSSA (Figure 3.2.2.1) and for tigecycline against 50 clinical isolates of 
MRSA (Figure 3.2.2.2) demonstrate that the MPC values were the same or within one 
doubling dilution on TSA and TSA + 5% SRBC.  The MPC90 for tigecycline against 
MSSA on TSA was 16 fold higher than the corresponding MIC90 while the MPC90 on 
TSA + 5% SRBC was 8 fold higher than the corresponding MIC90.  The MPC90 for 
tigecycline against MRSA was 4 fold higher than the corresponding MIC90 for testing 
done using TSA and TSA + 5% SRBC.  Therefore, tigecycline MPC values for MSSA 
and MRSA do not appear to be influenced by blood in the test media [84].  
3.3 The Use of BAK in Conjunction with gatifloxacin and moxifloxacin 
Benzalkonium chloride (BAK) is a cationic surface-acting agent presently being 
used as a preservative in the commercial preparation of Zymar® (0.3% gatifloxacin plus 
0.005% BAK), an antimicrobial agent used to treat ocular infections.  We assessed the 
impact of BAK on the MIC and MPC values of gatifloxacin and moxifloxacin against 
Gram-positive and Gram-negative organisms. We also determined the killing action of 
BAK alone and in conjunction with gatifloxacin against clinical isolates of MRSA. 
3.3.1 MIC Results 
Minimum inhibitory concentration (MIC) values were measured for clinical 
isolates of MRSA (n = 20), MSSA (n = 20), coagulase-negative staphylococci (CNS; n = 
20), S. pneumoniae (n = 20), P. aeruginosa (n = 20), and E. coli (n = 20) against 
gatifloxacin and moxifloxacin with and without BAK and against BAK alone.  
When conducting MIC assays with gatifloxacin or moxifloxacin and BAK the 
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Organism Test Media MPC50a (µg/ml) MPC90b (µg/ml) MPC Range (µg/ml) 
TSA 1 2 1 - 4 
MSSA 
TSA + 5% SRBC 0.5 1 0.25 - 2 
TSA 1 4 0.5 - 8 
MRSA 
TSA + 5% SRBC 0.5 4 0.5 - 4 
  MIC50a (µg/ml) MIC90b (µg/ml) MIC Range (µg/ml) 
MSSA Microbroth Dilution 0.063 0.125 0.031 - 0.125 
MRSA Microbroth Dilution 0.125 0.5 0.063 - 1 
 
Table 3.2.2.1: Summary of MIC and MPC results for tigecycline against 50 clinical isolates of MSSA and MRSA measured using different 
media. 
a The drug concentration inhibiting 50% of isolates tested 
b The drug concentration inhibiting 90% of isolates tested 
MIC = Minimum Inhibitory Concentration; MPC = Mutant Prevention Concentration; MSSA = Methicillin-susceptible 




Figure 3.2.2.1: Distribution values for 50 clinical isolates of MSSA against tigecycline. 
MPC = Mutant Prevention Concentration; MIC = Minimum Inhibitory Concentration; TSA = tryptic soy agar; SRBC = sheep red 




Figure 3.2.2.2: Distribution values for 50 clinical isolates of MRSA against tigecycline. 
MPC = Mutant Prevention Concentration; MIC = Minimum Inhibitory Concentration; TSA = tryptic soy agar; SRBC = sheep red 
blood cells; MRSA = Methicillin-resistant Staphylococcus aureus 
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concentration of BAK was kept constant at 50 µg/ml; gatifloxacin and moxifloxacin were 
first serially diluted in 96-well microtitre panels and BAK was then added so the final 
concentration of BAK in each well was 50 µg/ml.  A BAK concentration of 50 µg/ml 
was selected because it is the concentration of BAK present in the commercial 
preparation of Zymar® (i.e. 0.005% BAK).  The lowest drug concentration preventing 
growth of 90% of bacterial strains was recorded as the MIC90.  The MIC90 values of 
gatifloxacin and moxifloxacin alone and with BAK and of BAK alone against the study 
organisms are presented in Table 3.3.1.1. 
The MIC90 values (µg/ml) for BAK against Gram-positive organisms ranged from 
1.563 to 3.125 (MRSA = 3.125 µg/ml; MSSA = 1.563 µg/ml; CNS = 3.125 µg/ml; S. 
pneumoniae = 1.563 µg/ml).  BAK was less active against Gram-negative organisms with 
MIC90 values (µg/ml) of 12.5 for E. coli and 50 for P. aeruginosa.  The MIC90 values 
(µg/ml) for gatifloxacin and moxifloxacin against MRSA were both >4; against MSSA 
they were 2 and 1 respectively; 2 and 4 respectively against CNS; 1 and 0.125 
respectively against S. pneumoniae; 2 and 4 respectively for P. aeruginosa; and they 
were both >2 for E. coli.  All study organisms, with the exception of S. pneumoniae, were 
equally susceptible to either gatifloxacin or moxifloxacin with MIC90 values falling 
within one doubling-dilution when either antibiotic was used.  S. pneumoniae was more 
susceptible to moxifloxacin (MIC90 = 0.125 µg/ml) than gatifloxacin (MIC90 = 1 µg/ml). 
In the presence of BAK (50 µg/ml), the MIC90 values of gatifloxacin and 
moxifloxacin against all four Gram-positive organisms tested (MRSA, MSSA, CNS, and 
S. pneumoniae) were reduced to ≤0.008 µg/ml; a 100-fold to >500-fold reduction in 





BAK Gfx Gfx + BAKb Mfx Mfx + BAKb 
MRSA 20 3.125 >4 ≤0.008 >4 ≤0.008 
MSSA 20 1.563 2 ≤0.008 1 ≤0.008 
CNS 20 3.125 2 ≤0.008 4 ≤0.008 
S. pneumoniae 20 1.563 1 ≤0.008 0.125 ≤0.008 
P. aeruginosa 20 50 2 0.5 4 1 
E. coli 20 12.5 >2 ≤0.002 >2 ≤0.002 
 
Table 3.3.1.1: Summary of MIC90 results for 20 clinical isolates of Gram-positive and Gram-negative organisms against 
gatifloxacin and moxifloxacin with and without BAK and against BAK alone. 
a The drug concentration inhibiting 90% of isolates tested 
b BAK was added at a concentration of 50 µg/ml 
MIC = Minimum Inhibitory Concentration; MRSA = Methicillin-resistant Staphylococcus aureus; MSSA = Methicillin-susceptible 
Staphylococcus aureus; CNS = coagulase-negative staphylococci; BAK = Benzalkonium chloride; Gfx = Gatifloxacin; Mfx = 
Moxifloxacin 
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MIC90 values of gatifloxacin and moxifloxacin against Gram-negative organisms were 
also substantially lower in the presence of BAK (50 µg/ml); MIC90 values (µg/ml) of 0.5 
and ≤0.002 were measured for P. aeruginosa and E. coli respectively against gatifloxacin 
with BAK (50 µg/ml) and MIC90 values (µg/ml) of 1 and ≤0.002 for P. aeruginosa and E. 
coli respectively against moxifloxacin with BAK (50 µg/ml). The MIC90 of gatifloxacin 
and moxifloxacin against E. coli decreased by >500-fold in the presence of 50 µg/ml of 
BAK while the MIC90 of gatifloxacin and moxifloxacin against P. aeruginosa decreased 
by 4-fold in the presence of 50 µg/ml of BAK.  
  There was a substantial decrease in the MIC90 values of gatifloxacin and 
moxifloxacin against Gram-positive and Gram-negative organisms in the presence of 50 
µg/ml of BAK, however, to determine the actual concentration of BAK required to 
achieve these substantially reduced MIC90 values, MIC testing was completed with 
gatifloxacin and moxifloxacin against MRSA, MSSA, CNS, S. pneumoniae, P. 
aeruginosa, and E. coli in the presence of differing concentrations of BAK (0.391 µg/ml 
to 50 µg/ml).  The MIC90 values of gatifloxacin and moxifloxacin alone and with BAK at 
concentrations of 0.391 µg/ml to 50 µg/ml against the study organisms are presented in 
Tables 3.3.1.2 and 3.3.1.3 respectively.  The MIC90 of gatifloxacin and moxifloxacin 
against MRSA, MSSA, and S. pneumoniae decreased to ≤0.008 µg/ml in the presence of 
3.125 µg/ml of BAK and the MIC90 of gatifloxacin and moxifloxacin against CNS 
decreased to ≤0.008 µg/ml in the presence of 6.25 µg/ml of BAK [49].  Higher 
concentrations of BAK were needed to substantially reduce the MIC90 values of 
gatifloxacin and moxifloxacin against the Gram-negative organisms P. aeruginosa and E. 






























MRSA 3.125 >4 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 8 >8 >8 
MSSA 1.563 2 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.016 0.5 1 
CNS 3.125 2 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.5 2 4 4 
S. pneumoniae 1.563 1 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.063 0.5 0.5 
P. aeruginosa 50 2 0.5 4 ND ND ND ND ND ND 
E. coli 12.5 >2 ≤0.002 ≤0.002 ≤0.002 2 >2 >2 ND ND 
 
Table 3.3.1.2: Summary of MIC90 results for 20 clinical isolates of Gram -positive and Gram-negative organisms against gatifloxacin, 
BAK, and gatifloxacin with different concentrations of BAK. 
a The drug concentration inhibiting 90% of isolates tested 
MIC = Minimum Inhibitory Concentration; MRSA = Methicillin-resistant Staphylococcus aureus; MSSA = Methicillin-susceptible 






























MRSA 3.125 >4 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 4 4 4 
MSSA 1.563 1 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.25 0.5 
CNS 3.125 4 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.25 2 2 2 
S. 
pneumoniae 1.563 0.125 ≤0.008 ≤0.008 ≤0.008 ≤0.008 ≤0.008 0.031 0.125 0.125 
P. aeruginosa 50 4 1 4 ND ND ND ND ND ND 
E. coli 12.5 >2 ≤0.002 ≤0.002 ≤0.002 2 >2 >2 ND ND 
 
Table 3.3.1.3: Summary of MIC90 results for 20 clinical isolates of Gram-positive and Gram-negative organisms against moxifloxacin, 
BAK, and moxifloxacin with different concentrations of BAK. 
a The drug concentration inhibiting 90% of isolates tested 
MIC = Minimum Inhibitory Concentration; MRSA = Methicillin-resistant Staphylococcus aureus; MSSA = Methicillin-susceptible 
Staphylococcus aureus; CNS = coagulase-negative staphylococci; BAK = Benzalkonium chloride; Mfx = Moxifloxacin; ND = no data 
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 against P. aeruginosa was reduced to 0.5 µg/ml and 1 µg/ml respectively while 12.5 
µg/ml of BAK was required to reduce the MIC90 of gatifloxacin and moxifloxacin against 
E. coli to ≤0.002 µg/ml. 
3.3.2 MPC Results 
Mutant prevention concentration (MPC) values were measured for gatifloxacin 
and moxifloxacin, in the presence and absence of BAK, against clinical isolates of 
fluoroquinolone-resistant MRSA (n = 9) and one commercially available MSSA strain, 
ATCC 29213. The traditional agar dilution method was used to determine MPC values 
(Section 2.3.2).  The MPC90 of gatifloxacin against MRSA isolates was similar to that of 
moxifloxacin (≥4 µg/ml) and the MPC90 of BAK against the same MRSA isolates was 10 
µg/ml (Table 3.3.2.1).  The MPC90 values remained ≥4 µg/ml for gatifloxacin and 
moxifloxacin in the presence of 5 µg/ml BAK, however, in the presence of 7 µg/ml BAK, 
the MPC90 for moxifloxacin against MRSA decreased to ≤0.004 µg/ml.  In the presence 
of 9 µg/ml BAK, the MPC90 for gatifloxacin against MRSA decreased to ≤0.004 µg/ml.  
The addition of BAK at concentrations from 7 µg/ml to 9µg/ml lowered the MPC90 
(µg/ml) of gatifloxacin (≤0.004) and moxifloxacin (≤0.004) against MRSA by 1000-fold 
compared to gatifloxacin (≥4) or moxifloxacin (≥4) alone.  The presence of BAK at 
concentrations from 5 µg/ml to 7 µg/ml also decreased the MPC90 (µg/ml) of gatifloxacin 
(≤0.004) and moxifloxacin (≤0.004) against the commercially available MSSA strain, 




MIC90a (µg/ml) MPC90a (µg/ml) 
Organism 
















MRSA (n = 9) 3.125 ≥4 10 ≥4 ≥4 ≥4 ≥4 ≤0.004 ≤0.004 
MSSA (ATCC 29213) 0.781 0.063 7 ≥4 ≥4 ≤0.004 ≤0.004 ≤0.004 ≤0.004 
  MIC90
a (µg/ml) MPC90a (µg/ml) 
















MRSA (n = 9) 3.125 4 10 ≥4 ≥4 ≤0.004 ≤0.004 ≤0.004 ≤0.004 
MSSA (ATCC 29213) 0.781 0.031 7 ≥4 ≤0.004 ≤0.004 ≤0.004 ≤0.004 ≤0.004 
 
Table 3.3.2.1:Summary of MIC90 and MPC90 values for nine clinical isolates of MRSA and one commercially available MSSA strain (ATCC 
29213) against gatifloxacin, moxifloxacin, BAK, and gatifloxacin and moxifloxacin with different concentrations of BAK. 
a The drug concentration inhibiting 90% of isolates tested 
MIC = Minimum Inhibitory Concentration; MPC = Mutant Prevention Concentration; MRSA = Methicillin-resistant Staphylococcus 
aureus; MSSA = Methicillin-susceptible Staphylococcus aureus; BAK = Benzalkonium chloride; Gfx = gatifloxacin; Mfx = 
moxifloxacin 
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3.3.3 Time-Kill Results 
To determine the killing action of BAK, conventional time-kill studies were 
completed with differing concentrations of BAK against clinical isolates of MRSA (n = 
4).  The results of the time-kill studies are summarized in Tables 3.3.3.1 and 3.3.3.2 and 
Figures 3.3.3.1 and 3.3.3.2.  The killing action of BAK against MRSA isolates was 
measured using five different BAK concentrations: 10 µg/ml, 15 µg/ml, 20 µg/ml, 25 
µg/ml, and 50 µg/ml.  The highest concentration of 50 µg/ml was chosen as it 
corresponds to the concentration of BAK present in the commercial preparation of 
Zymar® (0.005% BAK).  The MRSA isolates were grown to a bacterial density of 105 
CFU/ml and colony counts were taken at 0, 5, 10, 15, 20, 25, 30, 60, 120, and 180 
minutes after the addition of BAK.  The log10-reduction and percent kill of viable cells 
was calculated at each time point for each bacterial isolate and averaged.   
The log10-reduction (percent kill) of viable cells increased substantially with 
increasing BAK concentration.  The log10-reduction (percent kill) of viable cells 180 
minutes after the addition of BAK were -0.4 (-48.17%), -1.0 (-78.27%), -4.3 (-99.90%), -
5.2 (-99.99%), and -5.5 (-100%) for BAK concentrations of 10 µg/ml, 15 µg/ml, 20 
µg/ml, 25 µg/ml, and 50 µg/ml respectively.  Bactericidal activity is associated with a 
greater than 3 log10-reduction of viable cells; in this case bactericidal activity was 
observed 10 minutes after the addition of 50 µg/ml BAK (log10-reduction = -5.5) to 
MRSA present at a concentration of 105 CFU/ml.  Log10-reductions of -3.0 or greater 
were also calculated 60 minutes following the addition of 25 µg/ml BAK (log10-reduction 
= -3.7) and 120 minutes following the addition of 20 µg/ml BAK (log10-reduction = -3.7).
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Log10 Reduction of Viable Cells 
Time (min) 
BAK 10 µg/ml BAK 15 µg/ml BAK 20 µg/ml BAK 25 µg/ml BAK 50 µg/ml 
5 0.006 0.022 -0.092 -0.222 -2.779 
10 0.051 -0.047 -0.187 -0.387 -5.512 
15 -0.018 -0.063 -0.492 -0.685 -5.512 
20 -0.041 -0.099 -0.840 -1.148 -5.512 
25 -0.075 -0.198 -1.172 -1.563 -5.512 
30 -0.117 -0.235 -1.477 -2.082 -5.512 
60 -0.200 -0.485 -2.723 -3.720 -5.512 
120 -0.273 -0.825 -3.699 -5.354 -5.512 
180 -0.378 -1.029 -4.317 -5.195 -5.512 
 
Table 3.3.3.1:  Log10-reduction of viable cells using different concentrations of BAK against 4 clinical isolates of MRSA. 




Figure 3.3.3.1: Log10-reduction of 4 clinical isolates of MRSA against differing concentrations of BAK. 
BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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Percent Kill (%) 
Time (min) 
BAK 10 µg/ml BAK 15 µg/ml BAK 20 µg/ml BAK 25 µg/ml BAK 50 µg/ml 
5 1.328 8.263 -17.965 -25.677 -99.804 
10 13.656 -4.931 -33.863 -30.819 -100.000 
15 -4.367 -6.588 -66.268 -59.440 -100.000 
20 -15.529 -14.451 -83.698 -80.269 -100.000 
25 -14.281 -28.070 -91.964 -85.294 -100.000 
30 -20.436 -34.666 -95.288 -95.031 -100.000 
60 -35.046 -60.581 -98.659 -99.704 -100.000 
120 -40.604 -77.144 -99.833 -100.000 -100.000 
180 -48.173 -78.271 -99.895 -99.999 -100.000 
 
Table 3.3.3.2: Percent Kill (%) of viable cells using different concentrations of BAK against 4 clinical isolates of MRSA. 




Figure 3.3.3.2: Percent Kill (%) of 4 clinical isolates of MRSA against differing concentrations of BAK. 
BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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 MIC and MPC studies (Sections 3.3.1 and 3.3.2) have demonstrated that the 
presence of BAK increases the antibacterial activity of gatifloxacin against MRSA 
isolates; lower MIC and MPC values were measured when gatifloxacin was used in 
conjunction with BAK than when used alone.  In order to determine the impact of BAK 
on the killing action of gatifloxacin, conventional time-kill studies were conducted using 
gatifloxacin, BAK, and gatifloxacin plus BAK against clinical MRSA isolates (n = 2).  
The MRSA isolates were grown to a bacterial density of 105 CFU/ml and colony counts 
were taken at 0, 5, 10, 15, 20, 25, 30, 60, 120, and 180 minutes after the addition of 
antimicrobial agent(s).  The log10-reduction and percent kill of viable cells was calculated 
at each time point.  Two clinical MRSA isolates were used for this time-kill assay and the 
results averaged.  The results of the time-kill studies are summarized in Tables 3.3.3.3 
and 3.3.3.4 and Figures 3.3.3.3 and 3.3.3.4. 
The log10-reduction (percent kill) of viable cells 180 minutes after the addition of 
antimicrobial agent(s) to MRSA isolates (n = 2) was -1.6 (-76.08%), -5.0 (-99.99%), and 
-5.4 (100%) for gatifloxacin, BAK, and gatifloxacin plus BAK respectively.  The 
concentration of gatifloxacin used in this assay was equivalent to the experimentally 
determined MIC value for each isolate and the concentration of BAK used was 25 µg/ml.  
Bactericidal activity is observed when BAK or gatifloxacin plus BAK are used against 
the clinical MRSA isolates with a greater than 5 log10-reduction in viable cells.  A less 
than 2 log10-reduction in viable cells is observed when gatifloxacin is used alone against 
clinical MRSA isolates indicating reduced bactericidal activity. 
Further conventional time-kill studies were completed to compare the killing 
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Log10-Reduction in Viable Cells 
Time (min) 
Gfx (MIC µg/ml) BAK (25 µg/ml) Gfx (MIC µg/ml) + BAK (25µg/ml) 
5 0.026 -0.084 -0.072 
10 -0.042 -0.130 -0.169 
15 -0.111 -0.392 -0.290 
20 -0.114 -0.740 -0.589 
25 -0.187 -1.051 -0.986 
30 -0.286 -1.563 -1.716 
60 -0.602 -3.304 -4.825 
120 -1.121 -5.199 -5.387 
180 -1.621 -4.960 -5.387 
 
Table 3.3.3.3: Log10-reduction of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK against 2 clinical isolates of MRSA. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
 
Percent Kill (%) 
Time (min) 
Gfx (MIC µg/ml) BAK (25 µg/ml) Gfx (MIC µg/ml) + BAK (25 µg/ml) 
5 7.614 -16.299 -14.793 
10 -8.426 -21.029 -29.284 
15 -20.789 -54.519 -45.898 
20 -12.377 -78.108 -71.825 
25 -19.826 -84.648 -88.667 
30 -29.158 -94.853 -97.597 
60 -41.098 -99.860 -99.998 
120 -53.764 -99.999 -100.000 
180 -76.079 -99.999 -100.000 
 
Table 3.3.3.4: Percent Kill (%) of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK against 2 clinical isolates of MRSA. 




Figure 3.3.3.3: Log10-reduction of 2 clinical isolates of MRSA against gatifloxacin, BAK, and gatifloxacin plus BAK. 




Figure 3.3.3.4: Percent Kill (%) of 2 clinical isolates of MRSA against gatifloxacin, BAK, and gatifloxacin plus BAK. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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activity of the commercial preparation Zymar® (0.3% gatifloxacin; 0.005% BAK) to the 
killing activity of gatifloxacin, BAK, and gatifloxacin plus BAK against clinical isolates 
of MRSA (n = 4).  The concentration of gatifloxacin and BAK in Zymar® is 3,000 µg/ml 
and 50 µg/ml respectively.  One drop of Zymar® has an approximate volume of 100µl.  
The amount of gatifloxacin and BAK in one drop or 100 µl of Zymar® is therefore 
approximately 300 µg and 5 µg respectively.  To reflect the concentration of 
antimicrobial agent administered to the eye, the concentration of gatifloxacin and BAK 
used in the time-kill assays were 300 µg/ml and 5 µg/ml respectively.  Very short time 
intervals were used in the time-kill studies with an ending time point of 15 minutes. 
The MRSA isolates were grown to a bacterial density of 105 CFU/ml and colony 
counts were taken at 0, 0.5, 1, 2, 3, 4, 5, 10, and 15 minutes after the addition of 
antimicrobial agent(s).  The log10-reduction and percent kill of viable cells was calculated 
at each time point.  Results from the four clinical MRSA isolates used in this time-kill 
assay were averaged.  The results of the time-kill studies are summarized in Tables 
3.3.3.5 and 3.3.3.6 and Figures 3.3.3.5 and 3.3.3.6.  The log10-reduction (percent kill) of 
viable cells 15 minutes after the addition of gatifloxacin, BAK, gatifloxacin plus BAK, 
and Zymar® was -0.6 (-53.89%), -0.0 (-9.30%), -0.4 (-51.65%), and -0.8 (-59.09%) 
respectively. Zymar® had the best killing action (log10-reduction = -0.8) followed by 
gatifloxacin alone, gatifloxacin plus BAK, and BAK alone, however, it is evident from 
the time-kill graphs (Figures 3.3.3.5 and 3.3.3.6) that 15 minutes after the addition of 
antimicrobial agent to a bacterial population of MRSA, there is very poor killing activity 
exhibited by all the antimicrobial agents and combinations of antimicrobial agents tested.  
There was less than a 1 log10-reduction of viable cells 15 minutes after addition of
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Log10-Reduction in Viable Cells 
Time (min) 
Gfx (300 µg/ml) BAK (5 µg/ml) Gfx (300 µg/ml)  + BAK (5 µg/ml) 
Zymar®  
(Gfx [300 µg/ml]  
+ BAK [5 µg/ml])a 
0 0.000 0.000 0.000 0.000 
0.5 -0.163 0.035 -0.193 -0.130 
1 -0.149 -0.027 -0.264 -0.223 
2 -0.194 -0.044 -0.175 -0.250 
3 -0.176 0.039 -0.287 -0.189 
4 -0.283 0.015 -0.270 -0.188 
5 -0.273 0.001 -0.295 -0.332 
10 -0.428 0.009 -0.416 -0.429 
15 -0.591 -0.043 -0.417 -0.834 
 
Table 3.3.3.5: Log10-reduction of viable cells using gatifloxacin, BAK, gatifloxacin plus BAK, and Zymar® against 4 clinical isolates of 
MRSA. 
a Concentration of Gfx and BAK present in one drop (≈100 µl) of Zymar® 




Figure 3.3.3.5: Log10-reduction of viable cells using gatifloxacin, BAK, gatifloxacin plus BAK, and Zymar® against 4 clinical 
isolates of MRSA. 
* Concentration of Gfx and BAK present in one drop (≈ 100 µl) of Zymar® 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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Percent Kill (%) 
Time (min) 
Gfx (300 µg/ml) BAK (5 µg/ml) Gfx (300 µg/ml)  + BAK (5 µg/ml) 
Zymar®  
(Gfx [300 µg/ml]  
+ BAK [5 µg/ml])a 
0 0.000 0.000 0.000 0.000 
0.5 -29.276 9.870 -34.127 -24.313 
1 -27.118 -5.698 -40.837 -38.020 
2 -34.270 11.372 -31.547 -42.286 
3 -31.803 9.551 -45.902 -33.269 
4 -41.943 4.682 -44.301 -33.400 
5 -41.475 1.243 -45.735 -48.905 
10 -49.344 3.649 -54.862 -54.541 
15 -53.885 -9.295 -51.651 -59.086 
 
Table 3.3.3.6: Percent Kill (%) of viable cells using gatifloxacin, BAK, gatifloxacin plus BAK, and Zymar® against 4 clinical isolates of 
MRSA. 
a Concentration of Gfx and BAK present in one drop (≈ 100 µl) of Zymar® 




Figure 3.3.3.6: Percent Kill (%) of viable cells using gatifloxacin, BAK, gatifloxacin plus BAK, and Zymar® against 4 clinical 
isolates of MRSA. 
* Concentration of Gfx and BAK present in one drop (≈ 100 µl) of Zymar® 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
  84 
antimicrobial agent(s).    
To investigate the effect of adding BAK at different time points during a time-kill 
study of gatifloxacin against clinical isolates of MRSA (n = 2), further conventional time-
kill assays were performed.  In these time-kill assays gatifloxacin, at a concentration 
corresponding to measured MIC values, was added at time 0 to a bacterial culture of 
MRSA at a bacterial load of 105 CFU/ml.  BAK at a concentration of 25 µg/ml was then 
added 5, 10, and 15 minutes after the addition of gatifloxacin.  Colony counts were taken 
at 0, 5, 10, 15, 20, 25, 30, 60, 120, and 180 minutes after the initial addition of 
gatifloxacin and the log10-reduction and percent kill of viable cells was calculated.  The 
results of these assays are found in Tables 3.3.3.7 and 3.3.3.8.  The results are also 
visually represented in Figures 3.3.3.7 and 3.3.3.8.     
The log10-reduction (percent kill) of viable cells 180 minutes after the addition of 
gatifloxacin was -1.6 (-76.08%), however when BAK was added 15, 10, and 5 minutes 
after the initial addition of gatifloxacin the log10-reduction (percent kill) of viable cells 
increased to -5.5 (-100%), -5.5 (-100%), and -5.6 (-100%) respectively.  The addition of 
BAK enhanced the killing action of gatifloxacin against clinical isolates of MRSA (n = 2) 
and bactericidal activity (>3 log10-reduction) was observed at 180 minutes when 
gatifloxacin and BAK were used in conjunction, regardless of the time point BAK was 
added.  In fact there was greater than a 3 log10-reduction of viable MRSA cells by 60 
minutes when BAK was added 10 minutes (log10-reduction = -5.5) or 15 minutes (log10-
reduction = -4.9) after gatifloxacin, and at 30 minutes when BAK was added 5 minutes 
(log10-reduction = -3.6) after gatifloxacin. 
To determine whether the killing action of gatifloxacin plus BAK against clinical
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Log10-Reduction of Viable Cells 
Time 
(min) Gfx  
(MIC µg/ml) 
BAK 
 (25 µg/ml) 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 15 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 10 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 5 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 0 minutes 
0 0.000 0.000 0.000 0.000 0.000 0.000 
5 0.026 -0.084 -0.021 0.001 -0.092 -0.072 
10 -0.042 -0.130 -0.161 -0.128 
-0.438 
(BAK 5 min) -0.169 
15 -0.111 -0.392 -0.277 
-0.470 
(BAK 5 min) 
-0.925 
(BAK 10 min) -0.290 
20 -0.114 -0.740 
-0.905 
(BAK 5 min) 
-1.065 
(BAK 10 min) 
-1.249 
(BAK 15 min) -0.589 
25 -0.187 -1.051 
-1.371 
(BAK 10 min) 
-1.784 
(BAK 15 min) 
-2.763 
(BAK 20 min) -0.986 
30 -0.286 -1.563 
-2.174 
(BAK 15 min) 
-2.845 
(BAK 20 min) 
-3.590 
(BAK 25 min) -1.716 
60 -0.602 -3.304 
-4.898 
(BAK 45 min) 
-5.509 
(BAK 50 min) 
-5.638 
(BAK 55 min) -4.825 
120 -1.121 -5.199 
-5.460 
(BAK 105 min) 
-5.509 
(BAK 110 min) 
-5.638 
(BAK 115 min) -5.387 
180 -1.621 -4.960 
-5.460 
(BAK 165 min) 
-5.509 
(BAK 170 min) 
-5.638 
(BAK 175 min) -5.387 
 
Table 3.3.3.7: Log10-reduction of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK added at different time points against 2 
clinical isolates of MRSA. 




Figure 3.3.3.7: Log10-reduction of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK added at different time points against 
2 clinical isolates of MRSA. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 15 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 10 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 5 minutes 
Gfx (MIC µg/ml) 
+ BAK (25 µg/ml) 
at 0 minutes 
0 0.000 0.000 0.000 0.000 0.000 0.000 
5 7.614 -16.299 -4.395 3.383 -18.540 -14.793 
10 -8.426 -21.029 -30.656 -25.367 
-63.382 
 (BAK 5 min) -29.284 
15 -20.789 -54.519 -36.713 
-65.989 
 (BAK 5 min) 
-87.564 
 (BAK 10 min) -45.898 
20 -12.377 -78.108 
-79.073  
(BAK 5 min) 
-91.316  
(BAK 10 min) 
-92.806 
 (BAK 15 min) -71.825 
25 -19.826 -84.648 
-95.459 
 (BAK 10 min) 
-98.350 
 (BAK 15 min) 
-99.808 
 (BAK 20 min) -88.667 
30 -29.158 -94.853 
-99.053 
 (BAK 15 min) 
-99.852 
 (BAK 20 min) 
-99.974 
 (BAK 25 min) -97.597 
60 -41.098 -99.860 
-99.998 
 (BAK 45 min) 
-100.000 
(BAK 50 min) 
-100.000 
 (BAK 55 min) -99.998 
120 -53.764 -99.999 
-100.000 
 (BAK 105 min) 
-100.000 
 (BAK 110 min) 
-100.000 
 (BAK 115 min) -100.000 
180 -76.079 -99.999 
-100.000 
 (BAK 165 min) 
-100.000 
 (BAK 170 min) 
-100.000  
(BAK 175 min) -100.000 
 
 
Table 3.3.3.8: Percent Kill (%) of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK added at different time points against 2 
clinical isolates of MRSA. 





Figure 3.3.3.8: Percent Kill (%) of viable cells using gatifloxacin, BAK, and gatifloxacin plus BAK added at different time points 
against 2 clinical isolates of MRSA. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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isolates of MRSA could be increased by first treating bacterial colonies with BAK and 
then adding gatifloxacin at different time points, conventional time-kill assays were 
performed.  These time-kill assays were an exact reversal of the previous time-kill assays.  
BAK, at a concentration of 25 µg/ml, was added at time 0 to a bacterial culture of MRSA 
at a bacterial load of 105 CFUs.  Gatifloxacin, at a concentration corresponding to 
measured MIC values, was then added 5, 10, and 15 minutes after the addition of BAK.  
Colony counts were taken at 0, 5, 10, 15, 20, 25, 30, 60, 120, and 180 minutes after the 
initial addition of BAK and the log10-reduction and percent kill of viable cells was 
calculated.  The results of these assays are found in Tables 3.3.3.9 and 3.3.3.10.  The 
results are also visually represented in Figures 3.3.3.9 and 3.3.3.10. 
The log10-reduction (percent kill) of viable cells 180 minutes after the addition of 
BAK was -5.0 (99.99%).  The addition of gatifloxacin 15, 10, and 5 minutes after the 
initial addition of BAK resulted in log10-reduction (percent kill) values of -5.4 (-100%), -
5.5 (-100%), and -5.5 (-100%) respectively 180 minutes after the initial addition of BAK.  
It is evident from the kill curves (Figures 3.3.3.9 and 3.3.3.10) that the addition of 
gatifloxacin had minimal impact on the killing action of BAK.    
3.4 Susceptibility Testing of Alexidine 
Alexidine is a cationic antimicrobial agent belonging to the bisbiguanide family.  
It has been used as an effective disinfectant in the dental industry for decades and is 
currently being looked at as a potential antimicrobial agent for ocular infections.  We 
completed MIC and MPC testing with alexidine against Gram-positive and Gram-
negative organisms often associated with ocular infection, including MRSA, MSSA, S. 
pneumoniae, P. aeruginosa, and Haemophilus influenzae.  We also looked at the killing
  
90 
Log10-Reduction of Viable Cells 
Time 
(min) BAK 
 (25 µg/ml) 
Gfx 
 (MIC µg/ml) 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 15 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 10 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 5 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 0 minutes 
0 0.000 0.000 0.000 0.000 0.000 0.000 
5 -0.084 0.026 0.003 -0.149 -0.211 -0.072 
10 -0.130 -0.042 -0.294 -0.240 
-0.419 
(Gfx 5 min) -0.169 
15 -0.392 -0.111 -0.611 
-0.601 
(Gfx 5 min) 
-0.837 
(Gfx 10 min) -0.290 
20 -0.740 -0.114 
-0.905 
(Gfx 5 min) 
-0.937 
(Gfx 10 min) 
-1.400 
(Gfx 15 min) -0.589 
25 -1.051 -0.187 
-1.305 
(Gfx 10 min) 
-1.590 
(Gfx 15 min) 
-2.132 
(Gfx 20 min) -0.986 
30 -1.563 -0.286 
-1.929 
(Gfx 15 min) 
-2.163 
(Gfx 20 min) 
-3.041 
(Gfx 25 min) -1.716 
60 -3.304 -0.602 
-4.350 
(Gfx 45 min) 
-5.242 
(Gfx 50 min) 
-5.274 
(Gfx 55 min) -4.825 
120 -5.199 -1.121 
-5.423 
(Gfx 105 min) 
-5.503 
(Gfx 110 min) 
-5.535 
(Gfx 115 min) -5.387 
180 -4.960 -1.621 
-5.423 
(Gfx 165 min) 
-5.503 
(Gfx 170 min) 
-5.535 
(Gfx 175 min) -5.387 
 
Table 3.3.3.9: Log10-reduction of viable cells using BAK, gatifloxacin, and BAK plus gatifloxacin added at different time points against 2 
clinical isolates of MRSA. 




Figure 3.3.3.9: Log10-reduction of viable cells using BAK, gatifloxacin, and BAK plus gatifloxacin added at different time points against 
2 clinical isolates of MRSA. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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Percent Kill (%) 
Time 
(min) BAK 




BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 15 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 10 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 5 minutes 
BAK (25 µg/ml) 
+ Gfx (MIC µg/ml) 
at 0 minutes 
0 0.000 0.000 0.000 0.000 0.000 0.000 
5 -16.299 7.614 1.412 -24.778 -37.831 -14.793 
10 -21.029 -8.426 -47.089 -41.261 
-60.241 
 (BAK 5 min) -29.284 
15 -54.519 -20.789 -74.028 
-72.444 
 (BAK 5 min) 
-83.881 
 (BAK 10 min) -45.898 
20 -78.108 -12.377 
-85.633  
(BAK 5 min) 
-88.886  
(BAK 10 min) 
-94.978 
 (BAK 15 min) -71.825 
25 -84.648 -19.826 
-93.042 
 (BAK 10 min) 
-95.285 
 (BAK 15 min) 
-99.114 
 (BAK 20 min) -88.667 
30 -94.853 -29.158 
-98.372 
 (BAK 15 min) 
-98.645 
 (BAK 20 min) 
-99.846 
 (BAK 25 min) -97.597 
60 -99.860 -41.098 
-99.994 
 (BAK 45 min) 
-100.000 
(BAK 50 min) 
-100.000 
 (BAK 55 min) -99.998 
120 -99.999 -53.764 
-100.000 
 (BAK 105 min) 
-100.000 
 (BAK 110 min) 
-100.000 
 (BAK 115 min) -100.000 
180 -99.999 -76.079 
-100.000 
 (BAK 165 min) 
-100.000 
 (BAK 170 min) 
-100.000  
(BAK 175 min) -100.000 
 
Table 3.3.3.10: Percent Kill (%) of viable cells using BAK, gatifloxacin, and BAK plus gatifloxacin added at different time points against 2 
clinical isolates of MRSA. 




Figure 3.3.3.10: Percent Kill (%) of viable cells using BAK, gatifloxacin, and BAK plus gatifloxacin added at different time points 
against 2 clinical isolates of MRSA. 
Gfx = gatifloxacin; BAK = Benzalkonium chloride; MRSA = Methicillin-resistant Staphylococcus aureus 
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activity of Alexidine against these pathogens. 
3.4.1 Comparative MIC Results 
Minimum inhibitory concentration (MIC) values were measured for clinical 
isolates of MRSA, MSSA, S. pneumoniae, P. aeruginosa, and H. influenzae against 
alexidine, levofloxacin, gatifloxacin, and moxifloxacin.  Using CLSI recommended 
procedures, MIC50 and MIC90 values were measured for each pathogen and antimicrobial 
agent [65].  The resulting MIC50 and MIC90 values are shown in Table 3.4.1.1. 
Measured MIC50 values (µg/ml) for alexidine, gatifloxacin, moxifloxacin, and 
levofloxacin against MRSA were 1, >2, 1, and 4 respectively; against MSSA 1, 0.063, 
0.031, and 0.125 respectively; against S. pneumoniae 0.5, 0.25, 0.125, and 0.5 
respectively; against H. influenzae 4, 0.016, 0.016, and 0.016 respectively; and against P. 
aeruginosa 4, 1, 1, and 1 respectively.  Measured MIC90 values (µg/ml) for alexidine, 
gatifloxacin, moxifloxacin, and levofloxacin against MRSA were 2, >2, 4, and >8 
respectively; against MSSA 2, 2, 1, and 4 respectively; against S. pneumoniae 0.5, 0.25, 
0.125, and 1 respectively; against H. influenzae 8, 0.031, 0.031, and 0.031 respectively; 
and against P. aeruginosa 4, 4, 8, and 4 respectively.  The results indicate that alexidine 
is more active in vitro (lower MIC values) against Gram-positive pathogens than against 
Gram-negative pathogens.  It is also evident that the fluoroquinolones (gatifloxacin, 
moxifloxacin, and levofloxacin) are more effective antimicrobial agents in vitro (lower 
MIC values) against clinical isolates of H. influenzae than alexidine. 
3.4.2 MPC Results 
 Mutant prevention concentration (MPC) values were measured for alexidine 
against clinical isolates of MRSA, MSSA, and S. pneumoniae. 
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  Organism n MIC50a (µg/ml) MIC90b (µg/ml) 
Alexidine MRSA 83 1 2 
 MSSA 24 1 2 
 S. pneumoniae 47 0.5 0.5 
 H. influenzae 41 4 8 
 P. aeruginosa 22 4 4 
     
Gatifloxacin MRSA 72 >2 >2 
 MSSA 24 0.063 2 
 S. pneumoniae 47 0.25 0.25 
 H. influenzae 29 0.016 0.031 
 P. aeruginosa 22 1 4 
     
Moxifloxacin MRSA 83 1 4 
 MSSA 24 0.031 1 
 S. pneumoniae 48 0.125 0.125 
 H. influenzae 27 0.016 0.031 
 P. aeruginosa 22 1 8 
     
Levofloxacin MRSA 83 4 >8 
 MSSA 24 0.125 4 
 S. pneumoniae 48 0.5 1 
 H. influenzae 29 0.016 0.031 
  P. aeruginosa 22 1 4 
 
Table 3.4.1.1: Comparative MIC50 and MIC90 values for alexidine, gatifloxacin, moxifloxacin, and levofloxacin against Gram-
positive and Gram-negative organisms. 
a The drug concentration inhibiting 50% of isolates tested 
b The drug concentration inhibiting 90% of isolates tested 
MIC = minimum inhibitory concentration; MRSA = Methicillin-resistant Staphylococcus aureus; MSSA = Methicillin-susceptible 
Staphylococcus aureus 
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3.4.2.1 Traditional Agar Dilution Method 
 Minimum inhibitory concentration (MIC) values and MPC values were measured 
for alexidine against clinical isolates of S. pneumoniae (n = 47).  MIC testing was 
performed using CLSI recommended guidelines and MPC testing was performed using 
the traditional agar dilution method (Section 2.3.2) [85]. The MIC50, MIC90, and MIC 
range values (µg/ml) were 0.5, 0.5, and 0.25 – 1 respectively.  The MPC50, MPC90, and 
MPC range values (µg/ml) were >16, >16, and 8 - >16 respectively.  The MPC50 and 
MPC90 values are greater than 32-fold higher than the MIC90 values measured for the 
same S. pneumoniae isolates.  
Mutant prevention concentration (MPC) testing of alexidine against MRSA and 
MSSA was attempted several times using the traditional established methodology 
(Section 2.3.2).  Tryptic soy agar plates containing 2-fold concentration increments of 
alexidine were created and MRSA isolates were inoculated at a density of ≥109 CFU/ml 
onto these plates.  Alexidine concentrations (µg/ml) of 1, 2, 4, 8, 16, and 32 were used.  
Unfortunately, each experimental attempt yielded non-reproducible results.  In general 
there was confluent bacterial growth on all drug dilution plates up to those containing 2 
µg/ml of alexidine.  On plates containing 4 µg/ml, 8 µg/ml, 16 µg/ml, and 32 µg/ml of 
alexidine, random single colonies were observed.  The single colonies would often be 
present on a drug plate with a concentration of 32 µg/ml but not on drug plates containing 
16 µg/ml or 8 µg/ml.  This “skipped well” phenomenon was observed for several isolates 
and when the experiment was repeated the results would be different (i.e. different wells 
would be skipped).   
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In one MPC assay using alexidine against clinical MRSA isolates (n = 56) the 
number of isolates growing at each drug concentration was recorded (Table 3.4.2.1.1).  
The number of isolates exhibiting the “skipped well” phenomenon were also recorded 
(Table 3.4.2.1.2).  Twenty-two MRSA isolates skipped wells covering a 4-fold difference 
in alexidine concentration, 3 MRSA isolates skipped wells covering an 8-fold difference 
in alexidine concentration, and 5 MRSA isolates skipped wells covering a 16-fold 
difference in alexidine concentration.  There was also one clinical MRSA isolate that 
skipped wells covering a 32-fold difference in alexidine concentration.  Nineteen MRSA 
isolates exhibiting skipped well phenomenon were back-tested and shown to have the 
same MIC values as experimentally determined prior to MPC testing.  
3.4.2.2 Modified Microbroth Dilution Method   
The modified microbroth dilution method for determining MPC values was used 
to determine the MPC values of alexidine against clinical isolates of MRSA and MSSA.  
The modified MPC method was used because the traditional MPC method generated non-
reproducible results (Section 3.4.2.1).  The modified MPC values for alexidine against 
clinical isolates of MRSA (n = 3) and MSSA (ATCC 29213) were both >64 µg/ml.  
Colony counts were performed to ensure that the bacterial density in the 96-well 
microtitre panel was ≥109 CFU/ml.  The measured MPC values are greater than 32-fold 
higher than the measure MIC values for alexidine against MRSA and MSSA. 
3.4.3 Time-Kill Results 
To determine the killing action of alexidine, conventional time-kill studies were 
completed with alexidine against clinical isolates of MRSA (n=3), MSSA (n = 1), S. 












Table 3.4.2.1.1: The number of MRSA isolates (n = 56) growing at different concentrations of alexidine. 













Table 3.4.2.1.2:  The number of MRSA isolates exhibiting various degrees of “skipped well” phenomenon during traditional 
MPC testing. 
MRSA = Methicillin-resistant Staphylococcus aureus 
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measured using three different drug concentrations corresponding to the MIC (µg/ml), 2 
x MIC (µg/ml), and 4 x MIC (µg/ml).  The bacterial isolates were grown to a bacterial 
density of 105 CFU/ml and colony counts were taken, in triplicate, at 0, 15, 30, 45, 60, 75, 
90, 120, and 180 minutes after the addition of alexidine.  The log10-reduction and percent 
kill of viable cells was calculated at each time point.  
In kill-studies using alexidine against clinical isolates of MRSA (n = 3) there was 
a greater than 3 log10-reduction of viable cells 180 minutes after the addition of alexidine 
when concentrations corresponding to the MIC, 2 x MIC, and 4 x MIC were used (Table 
3.4.3.1 and Figure 3.4.3.1).  In fact, there was a greater than 3 log10-reduction at 30 
minutes when a concentration of 2 x MIC was used and at 15 minutes when a 
concentration of 4 x MIC was used (Table 3.4.3.1 and Figure 3.4.3.1).  Using an 
alexidine concentration of the MIC against clinical isolates of MRSA, there was 99.99% 
kill of bacterial cells 90 minutes after the addition of alexidine (Table 3.4.3.2 and Figure 
3.4.3.2).  With an alexidine concentration corresponding to 2 x MIC and 4 x MIC was 
used against clinical isolates of MRSA there was a 100% kill of bacterial cells 45 minutes 
and 30 minutes after the addition of alexidine respectively (Table 3.4.3.2 and Figure 
3.4.3.2). 
In kill-studies using alexidine against a clinical isolate of MSSA there was a 
greater than 3 log10-reduction of viable cells 45 minutes after the addition of alexidine 
when concentrations corresponding to the MIC, 2 x MIC, and 4 x MIC were used (Table 
3.4.3.3 and Figure 3.4.3.3).  The kill-pattern was similar to that observed with alexidine 
against MRSA with a greater than 3 log10-reduction in viable cells calculated at 30 
minutes when a concentration of 2 x MIC was used and at 15 minutes when a 
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concentration of 4 x MIC was used (Table 3.4.3.3 and Figure 3.4.3.3).  At 180 minutes, 
99.99% of all viable cells were killed using an alexidine concentration of the MIC, while 
100% of all viable cells were killed using concentrations of 2 x MIC and 4 x MIC (Table 
3.4.3.4 and Figure 3.4.3.4). 
In kill-studies using alexidine against clinical isolates of S. pneumoniae (n = 3) 
there was a greater than 4 log10-reduction of viable cells 30 minutes after the addition of 
alexidine when concentrations of the MIC, 2 x MIC, and 4 x MIC were used (Table 
3.4.3.5 and Figure 3.4.3.5).  In fact, there was 100% kill of all viable cells at 60 minutes, 
30 minutes, and 15 minutes when alexidine concentrations corresponding to the MIC, 2 x 
MIC, and 4 x MIC were used respectively against clinical isolates of S. pneumoniae 
(Table 3.4.3.6 and Figure 3.4.3.6). 
Alexidine displayed perhaps the fastest killing action against clinical isolates of P. 
aeruginosa (n = 2).  There was a greater than 4 log10-reduction of viable cells 15 minutes 
after the addition of alexidine at concentrations corresponding to the MIC, 2 x MIC, and 
4 x MIC (Table 3.4.3.7 and Figure 3.4.3.7).  Furthermore, there was a calculated percent 
kill of 100% at 30 minutes after the addition of alexidine when a concentration of the 
MIC was used against clinical isolates of P. aeruginosa.  There was 100% kill of viable 
cells calculated just 15 minutes after the addition of alexidine when concentrations of 2 x 
MIC and 4 x MIC were used against clinical isolates of P. aeruginosa (Table 3.4.3.8 and 
Figure 3.4.3.8).  Alexidine was a potent killer of both Gram-positive and Gram-negative 
organisms; we calculated >99.99% kill of viable cells within 15 minutes using alexidine 
concentrations corresponding to 2 x MIC and 4 x MIC against all clinical isolates tested 
(MRSA, MSSA, S. pneumoniae, and P. aeruginosa).
  
101 
Log10-Reduction of Viable Cells 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -0.663 -2.191 -3.937 
30 -0.978 -3.460 -5.087 
45 -1.548 -4.122 -5.087 
60 -1.885 -4.170 -5.087 
75 -2.049 -5.085 -5.087 
90 -2.404 -5.260 -5.087 
120 -2.810 -5.260 -5.087 
180 -3.619 -5.260 -5.087 
 
Table 3.4.3.1: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of MRSA (n = 3)  
MIC = minimum inhibitory concentration; MRSA = Methicillin-resistant Staphylococcus aureus 
 
Percent Kill (%) 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -95.750 -99.753 -99.994 
30 -99.728 -99.988 -100.000 
45 -99.986 -100.000 -100.000 
60 -99.997 -100.000 -100.000 
75 -99.998 -100.000 -100.000 
90 -99.999 -100.000 -100.000 
120 -99.999 -100.000 -100.000 
180 -99.999 -100.000 -100.000 
 
Table 3.4.3.2: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of MRSA (n = 3) 




Figure 3.4.3.1: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of MRSA (n = 3) 




Figure 3.4.3.2: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of MRSA (n = 3) 
MIC = minimum inhibitory concentration; MRSA = Methicillin-resistant Staphylococcus aureus 
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Log10-Reduction of Viable Cells 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -1.371 -2.607 -4.217 
30 -2.565 -3.929 -5.217 
45 -3.857 -5.230 -5.217 
60 -4.556 -5.230 -5.217 
75 -4.778 -5.230 -5.217 
90 -5.079 -5.230 -5.217 
120 -5.079 -5.230 -5.217 
180 -5.079 -5.230 -5.217 
 
Table 3.4.3.3: The Log10-reduction of viable cells using different concentrations of alexidine against one clinical isolate of MSSA  
MIC = minimum inhibitory concentration; MSSA = Methicillin-susceptible Staphylococcus aureus 
 
 
Percent Kill (%) 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -95.750 -99.753 -99.994 
30 -99.728 -99.988 -100.000 
45 -99.986 -100.000 -100.000 
60 -99.997 -100.000 -100.000 
75 -99.998 -100.000 -100.000 
90 -99.999 -100.000 -100.000 
120 -99.999 -100.000 -100.000 
180 -99.999 -100.000 -100.000 
 
Table 3.4.3.4: The Percent Kill (%) of viable cells using different concentrations of alexidine against one clinical isolate of MSSA   




Figure 3.4.3.3: The Log10-reduction of viable cells using different concentrations of alexidine against one clinical isolate of MSSA  
MIC = minimum inhibitory concentration; MSSA = Methicillin-susceptible Staphylococcus aureus 
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Figure 3.4.3.4: The Percent Kill (%) of viable cells using different concentrations of alexidine against one clinical isolate of MSSA  
MIC = minimum inhibitory concentration; MSSA = Methicillin-susceptible Staphylococcus aureus 
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Log10-Reduction of Viable Cells 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -2.301 -4.048 -5.834 
30 -4.307 -6.334 -6.491 
45 -5.516 -6.334 -6.491 
60 -6.057 -6.334 -6.491 
75 -6.057 -6.334 -6.491 
90 -6.057 -6.334 -6.491 
120 -6.057 -6.334 -6.491 
180 -6.057 -6.334 -6.491 
 
Table 3.4.3.5: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of S. pneumoniae  
(n = 3)  
MIC = minimum inhibitory concentration 
 
Percent Kill (%) 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -99.302 -99.988 -100.000 
30 -99.990 -100.000 -100.000 
45 -99.999 -100.000 -100.000 
60 -100.000 -100.000 -100.000 
75 -100.000 -100.000 -100.000 
90 -100.000 -100.000 -100.000 
120 -100.000 -100.000 -100.000 
180 -100.000 -100.000 -100.000 
 
Table 3.4.3.6: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of S. pneumoniae  
(n = 3)  




Table 3.4.3.5: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of S. pneumoniae  
(n = 3) 




Figure 3.4.3.6: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of S. pneumoniae 
(n = 3)  
MIC = minimum inhibitory concentration 
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Log10-Reduction of Viable Cells 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -4.25 -6.487 -6.538 
30 -5.773 -6.743 -6.538 
45 -6.84 -6.743 -6.538 
60 -6.84 -6.743 -6.538 
75 -6.84 -6.743 -6.538 
90 -6.84 -6.743 -6.538 
120 -6.84 -6.743 -6.538 
180 -6.84 -6.743 -6.538 
Table 3.4.3.7: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of P. aeruginosa  
(n = 2)  
MIC = minimum inhibitory concentration 
 
 
Percent Kill (%) 
Alexidine Concentration Time (min) 
MIC (µg/ml) 2 x MIC (µg/ml) 4 x MIC (µg/ml) 
0 0.000 0.000 0.000 
15 -99.994 -100.000 -100.000 
30 -100.000 -100.000 -100.000 
45 -100.000 -100.000 -100.000 
60 -100.000 -100.000 -100.000 
75 -100.000 -100.000 -100.000 
90 -100.000 -100.000 -100.000 
120 -100.000 -100.000 -100.000 
180 -100.000 -100.000 -100.000 
Table 3.4.3.8: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of P. aeruginosa  
(n = 2)  




Figure 3.4.3.7: The Log10-reduction of viable cells using different concentrations of alexidine against clinical isolates of P. aeruginosa  
(n = 2)  




Figure 3.4.3.8: The Percent Kill (%) of viable cells using different concentrations of alexidine against clinical isolates of P. aeruginosa  
(n = 2) 
MIC = minimum inhibitory concentration
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4.0 DISCUSSION 
4.1 Methods to Simplify MPC Testing 
 The MPC method is potentially an important tool for the clinical microbiology 
laboratory because it can give a measured indication of the possibility or extent of 
resistance selection.  Unfortunately, the present protocol for MPC testing is too tedious 
and time-consuming to be used routinely in clinical microbiology susceptibility testing.  
In an attempt to make MPC testing more feasible for the clinical laboratory, we 
developed two new MPC methods:  the microbroth dilution method and the E-test 
method.  We also looked at the possibility of using linear regression as a method for 
extrapolating MPC values from experimentally measured MIC values.  
The modified microbroth dilution method, developed in our laboratory, is less 
time-consuming and labour-intensive than the traditional agar dilution method [78].  The 
microbroth dilution method requires a small volume (10 ml) of high-density bacterial 
inoculum for all organisms while the traditional MPC testing of S. aureus requires 100 ml 
of high-density bacterial suspension and traditional MPC testing of S. pneumoniae 
requires 500 ml of high-density bacterial suspension.  An incubation period of two hours, 
under appropriate conditions, is needed to achieve a bacterial density of ≥109 CFU/ml in 
a 10 ml suspension, whereas 18 to 24 hours of incubation under appropriate conditions 
are required when growing a bacterial suspension of ≥100 ml up to a bacterial density of 
≥109 CFU/ml. 
An advantage of the novel microbroth dilution MPC method is that inhibitory 
values (µg/ml) can be determined for different bacterial concentrations simultaneously. 
The result of performing consecutive 1:10 (700 µl into 7 ml) dilutions on the high-density 
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bacterial inoculum, following the two hour incubation under appropriate conditions, is a 
series of bacterial suspensions each with a different concentration (i.e. 101, 102, 103, 104, 
105, 106, 107, 108, and 109 CFU/ml).  By adding each of these dilutions to a separate row 
in a prepared 96-well microtitre panel (containing doubling dilutions of the antimicrobial 
agent of interest), it is possible to determine the concentration of antimicrobial agent 
required to inhibit different bacterial burdens.  For each row, the lowest drug 
concentration with no visible growth is recorded as the inhibitory concentration.  The 
bacterial burden of 105 CFUs corresponds to the MIC and the bacterial burden of 109 
CFUs (107 CFUs for S. pneumoniae) corresponds to the MPC.  The microbroth dilution 
method is therefore able to simultaneously determine MIC and MPC values for specific 
pathogen/antimicrobial agent combinations. 
 The microbroth dilution method shortens the time needed for MPC testing from 
five day to three days, making the microbroth dilution method more comparable to MIC 
testing in terms of assay duration.  In our experiments, we measured consistent MPC 
values using either the traditional- or the modified microbroth dilution- method [78].  
This finding suggests that the modified microbroth dilution method is a reliable method 
for determining MPC values; however, extension of this method to more bacteria-
antimicrobial agent combinations is necessary to further validate this procedure. 
The E-test method is commonly used in clinical laboratories as a fast and simple 
way of determining MIC values; we looked at the E-test as a possible method for 
determining MPC values.  The only real difference in determining an MIC value versus 
determining an MPC value is the bacterial density being used in the assay.  In MIC 
testing, bacterial density of 105 CFU/ml is used, whereas in MPC testing a bacterial 
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density of ≥109 CFU/ml is used.  Therefore, MPC testing using the E-test method is very 
similar to MIC testing using the E-test method; except a higher density bacterial 
suspension is placed on the agar plate prior to the addition of the E-test strip in MPC 
testing.   
Unfortunately, MPC values measured using the E-test method were not consistent 
with MPC values measured using the traditional agar dilution method.  The MPC values 
measured using the E-test method were substantially lower than the MPC values 
measured using the traditional agar dilution method.  The probable explanation for this 
lies in the fact that spontaneous mutations occur at a rate of 1x10-7 to 1x10-9 [68].  
Therefore, in a bacterial burdenof 109 CFUs, there may only be one or two mutants 
present.  The probabiliy of those mutants being positioned right along side the E-test strip 
on the agar plate is very low.  For this reason, the E-test is not an appropriate method for 
determining MPC values. 
We used linear regression models to determine whether it would be possible to 
extrapolate MPC values from experimentally determined MIC values for particular 
bacterial pathogens against particular antimicrobial agents.  Correlation coefficients (r2 
values) were calculated for several fluoroquinolones against five bacterial species and for 
three macrolides against S. pneumoniae using data from published and unpublished 
studies of clinical isolates.  We observed that MPC values and MIC values correlated 
poorly with the majority of r2 values falling below 0.5 [82].   
Low correlations between MIC and MPC values are likely to require a complex 
explanation.  Some of these isolates probably contain mutant subpopulations that vary 
considerably in relative abundance and drug susceptibility, which will contribute to a 
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wide variation in MIC values [82].  In fact, we have found isolates with the same MIC 
value whose MPC values have ranged over five twofold dilutions.  Unfortunately, 
because MPC values cannot be estimated accurately from MIC values, measurement of 
MPC values will continue to be required for each individual clinical isolate. 
While the E-test method and linear regression models do not appear to be 
appropriate methods for the determination of MPC values, the microbroth dilution 
method does appear to be a valuable method for MPC testing.  The microbroth dilution 
method represents an important advancement in MPC testing because it is less technically 
demanding and time-consuming than the currently available method; the agar dilution 
method.  Hopefully this improved novel method (microbroth dilution method) will 
ultimately allow for the facilitation of MPC testing in susceptibility testing in clinical 
microbiology laboratories.   
4.2 The Impact of Media on MPC Testing 
 While conducting MPC testing with clinical isolates of S. pneumoniae against 
tigecycline we noticed unusually high MPC values.  The MPC90 values we measured for 
S. pnuemoniae isolates against tigecyline were ≥500-fold higher than the corresponding 
measured MIC90 values.  The MPC values for most bacteria-antimicrobial agent 
combinations are generally 2 to 8 fold greater than the corresponding MIC values [83].  
After further testing we observed that the abnormally high MPC values were only 
measured when using media containing blood [80, 81].  MPC testing of tigecycline 
against MRSA and MSSA did not yield elevated MPC values in the presence of blood 
indicating the phenomenon may be limited to MPC testing of tigecycline against S. 
pneumoniae [84].     
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It is widely known that different bacterial organisms require different conditions 
for optimal growth.  Some of the factors that have the potential to affect the growth of 
bacterial organisms include: incubation conditions (temperature, atmosphere, light, 
duration of incubation, etc.), composition and pH of media (i.e. presence of blood), and 
the protocol used [64].  The Clinical and Laboratory Standards Institute (CLSI) has set 
forth guidelines to ensure that optimal growth conditions for bacterial isolates and proper 
preparation of antimicrobial agents is standardized in every clinical laboratory. For 
example, CLSI guidelines state susceptibility testing of S. pneumoniae should be done on 
media containing blood while susceptibility testing of Staphylococci spp. does not require 
blood; S. pneumoniae should also be incubated in CO2 while Staphylococci spp. should 
be incubated in ambient air (O2) [85, 86].  Unfortunately, the CLSI does not provide 
guidelines for standardized MPC testing. 
 The results of our experiments with S. pneumoniae and tigecycline indicate that 
MPC testing of S. pneumoniae against tigecycline should be avoided on media containing 
blood as it yields falsely elevated MPC values.  At this point, we do not have an 
explanation for the elevated MPC values observed in MPC testing of tigecycline against 
S. pneumoniae on blood.  Molecular experiments are likely to be required in order to 
elucidate the actual interaction between S. pneumoniae, tigecycline, and blood.  We 
speculate that the haemolytic quality of S. pneumoniae may be a factor in the observed 
interaction.  Our observations illustrate the profound effect media choice may have on 
susceptibility results.  It would be extremely beneficial to have standardized guidelines 
for MPC testing of various bacterial pathogens and antimicrobial agents as exists for MIC 
testing.  It is our hope that eventually bodies such as the CLSI in North America and the 
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European Committee on Antimicrobial Susceptibility Testing (EUCAST) in Europe will 
set forth MPC testing guidelines and perhaps ultimately MPC breakpoints.   
4.3 The Use of BAK in Conjunction with gatifloxacin and moxifloxacin 
   
 We conducted studies using BAK in conjunction with two commonly used 
ophthalmic fluroquinolones; gatifloxacin and moxifloxacin.  Both agents, Vigamox® 
(Alcon, Inc.) and Zymar® (Allergan, Inc.), are currently being used in competing 
commercial preparations for the treatment of bacterial conjunctivitis.  Vigamox® is a 
formula containing 0.5% moxifloxacin while Zymar® is a formula containing 0.3% 
gatifloxacin plus 0.005% BAK.  One of the main differences between Vigamox® and 
Zymar® is the addition of BAK to Zymar®.  There has been much debate over which 
product, Vigamox® or Zymar®, is more effective in the treatment of bacterial 
conjunctivitis [48, 87].   
Several studies have been conducted, both in vitro and in vivo, to determine which 
fourth generation fluoroquinolone, gatifloxacin or moxifloxacin, is better in terms of its 
ocular toxicity and antimicrobial activity.  The findings of these studies vary widely.  In 
recent in vitro studies, Sosa et al used corneal and conjunctival epithelial cells to look at 
the toxicity of gatifloxacin and moxifloxacin; they found that gatifloxacin was more toxic 
than moxifloxacin in both cell types [88].  Baez et al made similar observations using a 
mouse model; gatifloxacin was more toxic than moxifloxacin [89].  However, using a 
rabbit model, Herrygers et al found no difference in epithelial damage between 
gatifloxacin and moxifloxacin [90].  In human studies, Donnenfeld et al, reported that 
patients who received gatifloxacin reported better tolerability than patients who received 
moxifloxacin [91].   
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We conducted in vitro studies to look at the antimicrobial activity of gatifloxacin 
and moxifloxacin.  We measured similar MIC90 values (within one doubling dilution) for 
either antimicrobial agent (gatifloxacin or moxifloxacin) against Staphylococci spp., P. 
aeruginosa, and E. coli.  However, we did measure different MIC90 values for 
gatifloxacin and moxifloxacin against S. pneumoniae; 1 µg/ml and 0.125 µg/ml 
respectively (Section 3.3.1).  Our studies show that the antimicrobial activity of 
moxifloxacin is better (lower MIC value) against S. pneumoniae than gatifloxacin, but 
both agents have similar antimicrobial activity against the other pathogens we tested.  
Interestingly, in a recent retrospective cross-sectional study, Jensen et al found that the 
incidence of postoperative bacterial endophthalmitis was significantly higher in patients 
who had received moxifloxacin than in those who had received gatifloxacin in cataract 
surgery [87].  It is evident that further studies need to be conducted to determine which 
antimicrobial agent should be the agent of choice.  The debate as to which antimicrobial 
agent is “better” remains ongoing. 
To determine if the addition of BAK to the commercial preparation of Zymar® 
contributes to the clinical effect, we performed MIC and MPC experiments as well as 
time-kill assays with BAK alone and in combination with gatifloxacin and/or 
moxifloxacin.  Results from MIC studies indicate that the combination of gatifloxacin or 
moxifloxacin with BAK is more active (lower MIC values) than either fluoroquinolone 
without BAK.  In fact, MIC90 values for gatifloxacin plus BAK and moxifloxacin plus 
BAK against clinical isolates of MRSA were greater than 1000-fold lower than MIC90 
values for gatifloxacin or moxifloxacin alone. MIC90 values for gatifloxacin plus BAK 
and moxifloxacin plus BAK against all other clinical isolates tested (MSSA, CNS, S. 
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pnuemoniae, P. aeruginosa, and E. coli) were 4 to 500-fold lower than MIC90 values for 
gatifloxacin or moxifloxacin alone.  Furthermore, the actual concentration of BAK 
required to achieve such substantial reductions in MIC values is less than the 
concentration of BAK present in Zymar®, except for P. aeruginosa.  The concentration of 
BAK present in Zymar® is 50 µg/ml (0.005%), however, the concentration of BAK 
required to obtain the 1000-fold decrease in MIC90 values observed when used in 
conjunction with gatifloxacin and moxifloxacin against MRSA is 3.125 µg/ml [24]. 
Similar observations were made in MPC tests with BAK in conjunction with gatifloxacin 
and moxifloxacin; BAK lowered the MPC values of gatifloxacin and moxifloxacin 
against clinical isolates of MRSA. [19].  These findings indicate that BAK has a clinical 
impact on the MIC and MPC values of both Gram-positive and Gram-negative organisms 
in vitro. The mechanism of this enhanced in vitro activity remains unknown; however, 
one possibility is that BAK increases the facilitation of gatifloxacin or moxifloxacin into 
the bacterial cell.  Recall, BAK exerts its effect by causing the dissociation of the 
bacterial lipid bilayer [51].  This dissociation may provide “easy access” for gatifloxacin 
or moxifloxacin to enter the cell and exert its effect; inhibition of bacterial DNA 
synthesis [19].   
 Time-kill assays were performed using combinations of gatifloxacin and 
moxifloxacin with and without the addition of BAK.  First, studies were conducted to 
look at the killing action of BAK alone.  As expected, the higher the concentration of 
BAK, the greater the log10-reduction and percent kill of viable cells.  At a concentration 
of 50 µg/ml, the concentration of BAK in Zymar, there was a greater than 5-fold 
decrease in viable cells 10 minutes after the addition of BAK to clinical MRSA isolates.  
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This 5-fold decrease corresponded to a 100% kill of all viable cells.  The killing power of 
BAK decreased with decreasing concentration of BAK, indicating that BAK is a 
concentration dependent antimicrobial agent. 
 In time-kill assays looking at the action of BAK alone and in conjunction with 
gatifloxacin against clinical MRSA isolates, there was a marked decrease in viable cells 
when BAK was used in conjunction with gatifloxacin compared to gatifloxacin alone.  
The concentration of BAK was arbitrarily chosen to be 25 µg/ml and the concentration of 
gatifloxacin corresponded to the measured MIC values.  Interestingly, the combination of 
gatifloxacin plus BAK did not provide much better killing action than BAK alone.  The 
percent kill of viable MRSA cells 180 minutes after the addition of antimicrobial agent(s) 
was -99.99% for BAK alone and -100% for gatifloxacin plus BAK, compared to -76.08% 
for gatifloxacin alone.  This observation may be a result of the high concentration of 
BAK used (25 µg/ml).  The MIC90 of BAK against clinical isolates of MRSA is 3.125 
µg/ml.  If this study were to be conducted again, an antimicrobial agent concentration 
corresponding to the MIC should be used for both BAK and gatifloxacin.  With such a 
high concentration of BAK, it is possible that the killing-effect observed is not due to the 
combination of gatifloxacin plus BAK but due to BAK itself. 
   Additional time-kill assays were conducted that perhaps more accurately reflect 
the actual concentrations of BAK and gatifloxacin administered to the eye when using 
Zymar®.   Zymar® is a topical ophthalmic agent that is available as eye drops.  The 
concentrations of gatifloxacin and BAK in Zymar® are 3,000 µg/ml and 50 µg/ml 
respectively and one drop of Zymar® has an approximate volume of 100 µl.  Therefore, 
the approximate amounts of gatifloxacin and BAK administered to the eye in one drop of 
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Zymar® are 300 µg and 5 µg respectively. In a time-kill assay using concentrations of 
300 µg gatifloxacin and 5 µg BAK against clinical MRSA isolates, the percent kill 15 
minutes after the addition of antimicrobial agent(s) was -53.89 % for gatifloxacin alone, -
51.65% for gatifloxacin plus BAK, -59.09% for Zymar®, and -9.30% for BAK alone.  
These results indicate that BAK alone has very little killing activity at a concentration of 
5 µg/ml in the first 15 minutes after its addition to a bacterial population of MRSA.  
Interestingly, at a concentration of 5 µg/ml, the killing-action of gatifloxacin plus BAK 
against MRSA is similar to the killing-action of gatifloxacin alone.  This suggests that 
longer exposure to low BAK concentrations may be necessary to generate the high kill 
percentage observed when using higher concentrations of BAK. 
 The prescribed use of Zymar® is one drop in the infected eye every two hours [92]. 
However, anecdotal and personal experience suggests that the delivery of only one drop 
to the eye is difficult and often more than one drop is administered.  If two drops of 
Zymar® were inadvertently administered to the eye, the actual amount of gatifloxacin and 
BAK delivered to the eye would be 600 µg and 10 µg respectively.   In time-kill studies 
using a concentration of 300 µg/ml gatifloxacin plus 10 µg/ml BAK against clinical 
isolates of MRSA, Blondeau et al measured a percent kill of -55.20% 15 minutes after 
the addition of antimicrobial agents.  Blondeau et al also measured the percent kill of 300 
µg/ml gatifloxacin plus 15 µg/ml BAK and 300 µg/ml gatifloxacin plus 20 µg/ml BAK 
against clinical isolates of MRSA; -66.43% and 92.73% respectively 15 minutes after the 
addition of antimicrobial agents (Blondeau, et al., unpublished data, personal 
communication).  These studies hint toward the effect we would observe if 600 µg/ml of 
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gatifloxacin plus 10 µg/ml BAK were delivered to the eye (as they would be if two drops 
were administered at once); the killing activity of Zymar® would be enhanced. 
There is no doubt that BAK is a potent killer of the bacterial pathogen MRSA at 
high concentrations, however, it does not appear to contribute to the actual killing-
activity of Zymar® at concentrations that would be administered to the eye if one drop is 
used.  We have shown, however, that lower concentrations of BAK are able to 
substantially lower the MIC values of gatifloxacin and moxifloxacin against Gram-
positive and Gram-negative organisms.  Recall that 3.125 µg/ml of BAK lowered the 
MIC of gatifloxacin and moxifloxacin by 1000-fold against clinical isolates of MRSA.  
This is possible because MIC and MPC are measurements of inhibition of growth and not 
kill.  It is evident that further studies are needed to elucidate the true clinical impact of 
BAK.       
4.4 Susceptibility Testing of Alexidine 
There is an urgent need for new antimicrobial agents, especially those with 
activity against both Gram-positive and Gram-negative organisms [14, 43].  Alexidine is 
an antimicrobial agent that was previously used in the dental industry as an effective 
disinfectant and is currently being looked at as an agent for use in the field of 
ophthalmology [44].  Fluoroquinolones are currently the antimicrobial agent of choice in 
the ophthalmic community, however, as resistance to the fluoroquinolones continues to 
rise there is a need for new agents with better antimicrobial activity [22, 26, 29-31].  
Susceptibility testing of alexidine revealed that it is more active (lower MIC values) 
against Gram-positive pathogens than against Gram-negative pathogens.  Importantly, we 
also found that alexidine is more active against Gram-positive pathogens, especially 
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MRSA, than the fluoroquinolones gatifloxacin, moxifloxacin, and levofloxacin.  This 
suggests that alexidine may be a better choice for treating ocular infections than the 
currently indicated fluoroquinolones. 
We were unable to complete traditional MPC testing using alexidine against 
MRSA or MSSA.  When the microbroth dilution method for MPC testing was used we 
measured MPC90 values that were greater than 32-fold higher than the corresponding 
MIC90 values.  As previously stated, MPC values are generally 2 to 8 fold higher than 
MIC values [83].  If the MPC values measured using the microbroth dilution method are 
accurate then initial susceptibility testing indicates that alexidine may have a high 
likelihood for selecting resistance based on MPC measurements.  However, it is more 
likely that the MPC results measured for alexidine against MRSA and MSSA are 
inaccurate as there have been few if any reports of alexidine resistance at use 
concentrations, in spite of its widespread use for almost 50 years in clinical and domestic 
settings [16].  It is very unlikely that with such little resistance being reported over the 
last 50 years that the MPC values are accurate.  In support of this conclusion is the 
abnormally high MPC values measured when alexidine was tested against clinical 
isolates of S. pneumoniae.  The MPC90 values were greater than 32-fold higher than the 
corresponding MIC90 values for susceptibility testing of alexidine against clinical isolates 
of S. pnuemoniae.  Difficulties with MPC testing suggest that it may be necessary to 
modify the MPC protocol in order to measure MPC values of alexidine against MRSA, 
MSSA, or S. pneumoniae.  Such modifications may include different media, broth, and 
growth conditions. 
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When time-kill studies were performed, alexidine proved to have very potent 
killing activity against both Gram-positive and Gram-negative organisms.  Substantial 
bactericidal activity (>3fold log10-reduction) was observed very shortly after the addition 
of alexidine to bacterial isolates.  In fact, we calculated >99.999% kill of viable cells 15 
minutes after the addition of alexidine at concentrations corresponding to 2 x MIC and 4 
x MIC against clinical isolates of MRSA, MSSA, S. pneumoniae, and P. aeruginosa. 
Initial susceptibility testing of alexidine indicates that it is potentially a very 
potent antimicrobial agent with good activity against both Gram-positive and Gram-
negative organisms. 
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6.0 APPENDIX A 
  
6.1 Solutions and Media 
   
  MHB 
  Add 21 g to 1 L of distilled water and then autoclave 
 
  Skim Milk 
  Add 200 g to 1 L of distilled water and then autoclave 
 
  sTHB 
Add 15 g of granulated agar and 30 g of THB to 1 L of distilled water and 
autoclave 
  
  THB 
  Add 30 g to 1 L of distilled water and then autoclave 
 
  TSA 
  Add 40 g to 1 L of distilled water and then autoclave 
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7.0 APPENDIX B 
 
 7.1 Suppliers 
 
  7.1.1 Media 
  
 Chocolate Agar Plates  PML Microbiologicals, Winnipeg, MB 
 Granulated Agar   Becton Dickinson, Sparks, MD 
 Mueller Hinton Broth (MHB)  Becton Dickinson, Sparks, MD 
 Todd Hewitt Broth (THB)  Becton Dickinson, Sparks, MD 
 Tryptic Soy Agar (TSA)  Becton Dickinson, Sparks, MD 
 5% Sheep Red Blood Cells   Oxoid, Ryegate, MT 
  
  7.1.2 Antimicrobial Agents 
  
Alexidine (solution)  – Bausch and Lomb Pharmaceuticals Inc., Rochester, NY,  
U.S.A. 
Benzalkonium chloride (BAK) (solution) – Allergan Inc., Irvine, CA, U.S.A. 
Gatifloxacin (powder) – Bristol Myers Squibb, Montreal, QC, Canada 
Gatifloxacin (E-test)- AbBiodisk, U.S.A. 
Gemifloxacin (powder) – Glaxo Smith Kline Pharmaceuticals, Collegeville, PA, 
U.S.A.; Oscient Pharmaceuticals, Waltham, MA, U.S.A. 
Levofloxacin (solution) – Janssen Ortho, Toronto, ON, Canada 
Moxifloxacin (powder) – Bayer Pharmaceutical, Toronto, ON, Canada 
Tigecycline (powder) – Wyeth Pharmaceuticals, Collegeville, PA, U.S.A 
Vigamox® (commercial solution) – Alcon, Fort Worth, TX, U.S.A. 
Zymar® (commercial solution) – Allergan Inc., Irvine, CA, U.S.A 
 
 7.1.3 Reagents and Chemicals 
95% Alcohol    Commercial Alcohols Inc., Brampton, ON 
Saline     Baxter, Deerfield, IL 
Skim Milk    Becton Dickinson, Sparks, MD 
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 7.1.4 Disposable Labware 
10 µl Pipette Tips    Fisher Scientific, U.S.A. 
200 µl Pipette Tips    VWR International, Edmonton, AB 
5000 µl Pipette Tips    Fisher Scientific, U.S.A. 
96-Well Microtitre Panels   Sarstedt, Newton, NC 
Corning Cryovials    Corning Inc., Corning, NY 
Cuvettes     Fisher Scientific, U.S.A. 
Disposable Centrifuge Tube (15 ml)  Fisher Scientific, U.S.A. 
Glass Tubes     Fisher Scientific, U.S.A. 
Latex Gloves     Best, Coaticook, QC 
McFarland Tubes    Fisher Scientific, U.S.A. 
Pasteur Pipettes    Samco Scientific, U.S.A. 
Sterile Plastic Petri Plates   Fisher Scientific, U.S.A. 
Swabs      Puritan, Guilford, ME 
Wooden Applicator Sticks   Fisher Scientific, U.S.A. 
  
 7.1.5 Equipment 
10 µl and 300 µl Multichannel Pipettor Fisher Scientific, U.S.A. 
20 µl, 200 µl, and 1 ml Pipettors  Gilson Co., Inc., Lewis Center, OH  
 5000 µl Pipettor    Fisher Scientific, U.S.A. 
 -70°C Freezer     Forma Scientific Inc., Marjetta, OH 
 Avanti J-E Centrifuge    Beckman Coulter, Palo Alto, CA 
 CO2 Incubator     Forma Scientific Inc., Marjetta, OH 
 Colorimeter     Hach Company, Loveland, CO 
 Oxygen Incubator    Thermo Fisher Scientific, U.S.A. 
 Spectrophotometer    Pharmacia, Cambridge, England 
 Vortex Mixer     Fisher Scientific, U.S.A. 
 Water Bath     Mandel Scientific Co., Guelph, ON 
 Weigh Scale – Mettler PC440  DeltaRange, Zurich, Switzerland 
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8.0 APPENDIX C  
 8.1 Preparation of Antimicrobial Agents 
Alexidine  
This agent is available in solution at 400 µg/ml.  Dilute to the desired 
concentration 
 
Benzalkonium chloride (BAK)  




Dissolve 0.035 g into 10 ml of sterile distilled water.  At 93.3% purity, the final 
concentration is 3265 µg/ml 
 
Gemifloxacin  
Dissolve 0.1 g into 8 ml of sterile distilled water.  At 75.4% purity, the final 
concentration is 9425 µg/ml 
 
Levofloxacin  




Add 0.02 g to 10 ml of sterile distilled water.  At 87.8% purity, the final 
concentration is 1756 µg/ml 
 
Tigecycline  
Add 0.1 g into 10 ml of sterile distilled water.  At 100% purity, the final 
concentration is 10,000 µg/ml 
 
Vigamox®  
This agent is a commercial solution available at 0.5%.  The active antimicrobial 
agent is moxifloxacin (5000 µg/ml)  
 
Zymar®  
This agent is a commercial solution available at 0.3%.  The active antimicrobial 
agent is gatifloxacin (3000 µg/ml).  BAK is present as a preservative 0.005% (50 
µg/ml)  
 
